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Abstract 
 
The blood coagulation Factor XIII (FXIII) is a transglutaminase catalyzing γ-glytamyl ε-
lysine crosslinks between various molecules. It is most known for its role in crosslinking 
fibrin and stabilizing the blood clot in the process of coagulation in wound healing. The 
Factor XIII is also essential in maintaining pregnancy, and recurrent spontaneous abortions 
are reported in FXIII deficient patients.   
The localization and the role of FXIII in the development of the placenta were investigated in 
this study. Preliminary, FXIII was found to be located in macrophages, and in this study we 
verified by immunoblotting and mass spectrometry that FXIII is present in the decidual part 
of the placenta. The effect of FXIII on trophoblastic invasion during placental development 
was also examined. The invasion process was studied with the Boyden chamber assay using 
both an immortalized trophoblast cell line (HTR-8/SVneo), and primary culture of 
extravillous trophoblasts.   
A significant effect of FXIII on inhibition of invasion using trophoblast cell line was found, 
but no effect was observed with the primary culture. The cause of the inhibition on invasion 
observed with the cell line was ruled out to be caused by other indirect effects of FXIII, such 
as cytotoxicity, effect on secretion of matrix metalloproteases and proliferation. The results 
showed unfortunately great variability; therefore better controls must be included in the 
assays in order to obtain more reliable results.   
Future perspectives are to optimize the existing method or to use another technique to study 
the more in vivo approach on invasion using primary culture. Later, it would be interesting to 
examine the proteomics of FXIII; to identify the molecules involved in crosslinking by FXIII 
in placental development. This would allow us to understand more of the physiology of FXIII 
and its role in placental development which could aid in recurrent abortion managements.   
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Sammendrag 
 
Blodkoaguleringsfaktoren Faktor XIII (FXIII) er en transglutaminase som katalyserer γ-
glytamyl ε-lysin kryssbinder mellom ulike molekyler. Faktoren er mest kjent for sin rolle i 
kryssbinding av fibrin og stabilisering av blodlevring under koaguleringsprosessen i 
sårheling. Faktor XIII er også viktig for opprettholdelsen av svangerskap, og gjentatte 
spontanaborter er rapportert hos pasienter med FXIII mangel. 
 
I dette studiet ble lokalisering av FXIII og faktorens rolle i utvikling av morkaken (lat.: 
placenta) under graviditet undersøkt. FXIII ble innledningsvis lokalisert i makrofager i 
morkaken, og i denne studien ble det bekreftet ved immunoblotting og massespektrometri at 
FXIII er tilstede i livmorshinnen (lat.: decidua) i morkaken. FXIIIs innvirkning på invasjon av 
trofoblastceller under graviditet ble også undersøkt. Invasjonsprosessen ble studert med 
Boyden kammer ved hjelp av både en trofoblast-cellelinje (HTR-8/SVneo), og primær kultur 
av ekstravilløse trofoblaster. 
 
En signifikant effekt av FXIII på hemming av invasjonen ved bruk av trofoblast-cellelinje ble 
funnet, men ingen effekt ble observert med primær kultur. Årsaken til hemming på invasjonen 
observert med cellelinjen ble utelukket å være forårsaket av andre indirekte effekter av FXIII, 
for eksempel cytotoksisitet, effekt på utskillelsen av matrix metalloproteaser og proliferasjon. 
Resultatene viste dog store variasjoner, og for å oppnå mer pålitelige resultater må bedre 
kontroller inkluderes i analysene. 
 
Fremtidige perspektiver er optimalisering av den brukte metoden eller utprøving av en annen 
teknikk for å studere en mer in vivo tilnærming på invasjonen med primær kultur. Senere vil 
det være interessant å undersøke FXIII proteomisk for å identifisere molekyler involvert i 
kryssbinding av FXIII i utvikling av morkaken. Dette ville tillate oss å forstå mer av 
fysiologien til FXIII og dens rolle under graviditet og igjen styrke behandlingen av gjentatt 
spontanabortering ved FXIII mangel.   
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Abbreviations 
 
AP-FXIII  Activation peptide of Factor XIII 
APS   Ammonium persulfate 
BrdU   5-Bromo-2’-deoxy-Uridine 
CT   Cytotrophoblast 
ECM   Extracellular matrix 
EVT   Extravillous trophoblasts 
F13A1   Gene encoding human Factor XIII subunit A 
FCS   Fetal calf serum  
FXIII   Factor XIII 
FXIIIa   Activated Factor XIII 
FXIII-A  Factor XIII subunit A monomer 
FXIII-A2*  Activated Factor XIII subunit A dimer 
FXIII-A2’  Homodimer of FXIII-A without activation peptide 
FXIII-B  Factor XIII subunit B monomer 
FXIII-A2B2  Tetrameric form of FXIII 
HBSS   HANKS’ balanced salt solution 
HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
kb   Kilo bases 
kDa   Kilo Dalton 
MMP   Matrix metalloproteinase 
PCR   Polymerase chain reaction 
rFXIII   Recombinant FXIII 
SDS   Sodium dodecyl sulphate 
ST   Syncytiotrophoblast 
TBS-T   Tris buffered saline tween-20 
TIMP    Tissue inhibitor of metalloproteases 
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1. Introduction 
 
1.1 Factor XIII 
Factor XIII was first mentioned as a “serum factor” in 1944, when Robbins studied the 
formation of fibrin from fibrinogen, a necessary step in coagulation of blood. Robbins  found 
that in addition to the already known necessity of calcium ions, a serum factor was needed in 
order to render the clot insoluble in weak acid (Robbins, 1944). A few years later, this serum 
factor was discovered by Laki and Lorand  and it was then called the “fibrin stabilizing 
factor” or the “Laki-Lorand factor” (Laki and Lorand, 1948). The fibrin stabilizing factor was 
first purified by Loewy et al. in 1957 and its enzymatic character and structure were studied 
thoroughly in the following years. In 1960, Duckert et al. discovered that its medical 
correlation was related to hemorrhagic diathesis
1
 in a patient deficient in the fibrin stabilizing 
factor. Three years later, the International Committee on Blood Clotting Factors recognized 
the fibrin stabilizing factor as a blood clotting factor and was thereafter designated Factor XIII 
(FXIII).   
 
1.1.1 Functions of FXIII 
The Factor XIII is an important blood coagulation factor participating in the last step of the 
clotting cascade (Figure 1.1). The factor facilitates the formation of a stable blood clot after 
tissue damage, preventing excessive bleeding and aiding wound healing (Lauer et al., 2002). 
Activated FXIII (FXIIIa) acts as a transglutaminase
2
 to form intermolecular γ-glutamyl ε-
lysine crosslinks between fibrin fragments, the main protein in a blood clot (Pisano et al., 
1968). The crosslinks stabilizes the clot network and increases its tensile strength (Shen and 
Lorand, 1983). Without the formation of the interlacing fibrous network, hemostasis
3
 would 
be impaired by low resistance to degradation of the fibrin network.  
                                                 
1
 Hemorrhagic diathesis: An inherited predisposition to excessive bleeding. 
2
 Transglutaminase: Enzyme that catalyze the linking between a free amine-group on proteins to the γ-
carboxamide group of protein-bound glutamine. 
3
 Hemostasis: The process to stop bleeding by coagulation and constriction of blood vessels. 
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Figure 1.1: The last step of the blood coagulation cascade (After www.thrombosisadviser.com). 
Tissue damage leads to activation of the blood clotting cascade where the enzyme thrombin is 
activated. Thrombin catalyzes the formation of fibrin from fibrinogen and also the activation of Factor 
XIII. The activated FXIII forms covalent bonds between the fibrin monomers and renders the clot into 
a more stable and strong protein network.  
 
FXIII can crosslink many proteins other than fibrin, such as α2-Plasma Inhibitor which 
inactivates the enzyme plasmin, the main protein responsible for fibrinolysis (Sakata and 
Aoki, 1980). Not all substrates of FXIII are coagulation related, some are adhesive and 
extracellular matrix proteins, as well as intracellular cytoskeletal and contractile proteins 
(TRANSDAB database; http://genomics.dote.hu/wiki).  
Since adhesive proteins are also substrates of FXIII, it can be said that the FXIII additionally 
has a role as an adhesive molecule, anchoring cells and proteins together. FXIII has been 
found to crosslink fibronectin, a structural component of the connective tissue, at matrix 
assembly sites and thus enhancing the formation of extracellular matrix (Barry and Mosher, 
1988). Moreover, Dardik et al. discovered in 2002 that FXIII is involved in adhesion of 
platelets to endothelial cells via integrins
4
 and postulated that this facilitation of cell 
attachment may be important in tissue remodeling and wound repair.     
                                                 
4
 Integrins: Cell receptors that mediates attachment between cells and tissue. 
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As cytoskeletal and contractile proteins such as actin and myosin are also substrates of FXIII, 
it has been proposed that FXIII may be involved in cytoskeletal remodeling by enhancing 
crosslinking between glutamic acid and lysine in actin polymerization (Cohen et al., 1980). 
FXIII has also been proven to have an effect in angiogenesis by promoting remodeling and 
sprouting of new capillaries (Haroon et al., 1999). Dardik et al. postulated in 2003 that the 
proangiogenic effect is due to down regulation of an antiangiogenic factor. 
 
1.1.2 Structure of FXIII 
FXIII circulates in plasma as a heterotetramer of two catalytic A-subunits (FXIII-A) and two 
carrier B-subunits (FXIII-B) (Schwartz et al., 1971). The FXIII-B subunits can be found in 
plasma both as the heterotetramer and in free form. FXIII-A is found in plasma bound in the 
heterotetramer, however, only homodimers of the A-subunit are present intracellularly. The 
enzymatic activity of FXIII is located on the FXIII-A subunits, and the B-subunits acts 
therefore only as transporter proteins in plasma to stabilize and protect the A-subunits  (Saito 
et al., 1990).  
The gene coding for human FXIII-A subunit (F13A1) is 160 kb long and is located at 
chromosome position 6p24-25 (Board et al., 1988), while the gene for human FXIII-B is 
shorter with 28 kb length and localized to chromosome 1q31-32.1 (Webb et al., 1989). The 
subunit FXIII-A consists of 730 amino acids and has a molecular weight of 83 kDa  
(Takahashi et al., 1986), whereas the FXIII-B consists of 641 amino acids and weighs 76.5 
kDa (Ichinose et al., 1986b).   
 
1.1.3 Cellular origin of FXIII 
The FXIII-A circulating in the blood is derived from the bone marrow, which was determined 
by analyzes of phenotype change after bone marrow transplantation. Wölp et al. showed that 
the FXIII-A phenotype changed from origin phenotype to donor phenotype after the 
transplantation (Wölpl et al., 1987). In the same study, the authors presented also that FXIII-B 
phenotype did not change after bone marrow transplantation, but after liver transplantation, 
indicating therefore that FXIII-B is synthesized in the hepatocytes of the liver.  
7 
 
The homodimer of FXIII-A is mainly present in platelets (Luscher, 1957), megakaryocytes 
(Kiesselbach and Wagner, 1972), as well as monocytes and macrophages (Henriksson et al., 
1985). FXIII-A has also been found in macrophages in the placenta and in the uterus (Adány 
et al., 1988). The secretion mechanism of FXIII-A from cells is not known as there has not 
been found a secretion peptide signal (Ichinose et al., 1986a, Ichinose and Davie, 1988). Some 
controversial theories suggested that release to plasma occurs during rupture of cells (Kaetsu 
et al., 1996). More recently it was demonstrated that a non-classical mechanism, requiring 
structures adjacent to the plasma membrane containing trans-Golgi network proteins, is 
involved in the secretion of FXIII (Cordell et al. 2010). 
 
1.1.4 Activation of FXIII 
FXIII is a zymogen
5
 and needs activation by the concerted action of thrombin and calcium 
ions (Figure 1.2). FXIII is proteolytically cleaved between Arg-37 and Gly-38 by thrombin to 
release the activation peptide (AP-FXIII), yielding a peptide of 694 amino acids (FXII-A2’) 
(Takahashi et al., 1986). Calcium ions cause both the dissociation of B-subunits (Lorand et 
al., 1993) and exposure of the active site on the A-unit via conformational change (Hornyak 
and Shafer, 1991). FXIII is also inactivated again by thrombin due to a delayed cleavage at 
Lys-513, yielding two peptides of 56 kDa and 24 kDa (Takahashi et al., 1986).  
 
Figure 1.2: Proteolytic activation of plasma FXIII (Muszbek et al., 2011). Thrombin cuts the 
activation peptide (AP-FXIII) from the FXIII-A2B2 tetramere. In presence of Ca
2+
 the FXIII-B subunits 
dissociate and the remaining protein without the activation peptide (FXIII-A2’) undergoes a 
conformational change to complete the activation of FXIII (FXIII-A2
*
). 
                                                 
5
 Zymogen: Inactive precursor enzyme. 
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Human FXIII deficiency with less than 1% FXIII activity, although rare, occurs throughout 
the population with an incidence of 1 in 5 million people (Ichinose, 2001). Lack of functional 
FXIII may lead to poor wound healing, intracranial hemorrhage and recurrent miscarriages at 
early stages of pregnancy (Duckert et al., 1960, Fisher et al., 1966, Larsen et al., 1990). The 
roles of FXIII in wound healing and blood coagulation are well known, but the precise role of 
FXIII in maintaining pregnancy is still left to uncover.  
 
1.2 Placental development 
The placenta is the organ that forms the interface between the maternal tissue and the fetal 
tissue, and is developed from both fetal and maternal origin (Alsat et al., 1999). The placenta 
allows nutrient and gas exchange between the fetus and the mother, and it is also a producer 
of essentials pregnancy hormones such as progesterone and estrogens (Sadler, 2012). The 
placenta also provides a selective and immunological barrier, protecting the fetus against 
infectious agents and rejection from maternal tissue.   
 
1.2.1 Implantation of the embryo 
The development of the placenta starts at the implantation period of pregnancy, which is the 
attachment and embedding of the embryo in the uterus. Implantation begins around 6-7 days 
after conception, when the fertilized egg has migrated from the uterine tube to the uterine 
cavity and divided several times along its way (Sadler, 2012). At the stage of implantation the 
embryo is called a blastocyst, consisting of between 107 and 256 cells (Baergen and 
Benirschke, 2010).  The blastocyst consists of an inner cell mass, which is the stem cells that 
will form the later embryo, and the outer cells, which are the trophoblasts that surround the 
blastocyst cavity and will form the embryonic part of the placenta (Figure 1.3). Before 
implantation the blastocyst is enveloped by a protective layer called the pellucid zone.  
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Figure 1.3: Blastocyst inside the pellucide zone (2) [www.embryology.ch]. The blastocyst consists of 
the embryoblasts (1, inner stem cells) and the trophoblasts (3, outer cells) which are arranged so that 
a blastocyst cavity (4) appears.             
At the 5
th
 day after conception, the blastocyst hatches from the pellucid zone by release of 
proteases from the trophoblast cells. The blastocyst orients its embryonic pole in a correct 
way to the endometrium, and the blastocysts and endometrium come in physical contact with 
each other, a process called apposition. To allow the following implantation, the maternal 
uterine mucosa must be in its implantation window in the secretory phase of the menstrual 
cycle where the endometrium is prepared for reception of the embryo (Sunder and Lenton, 
2000). After the apposition of the embryo, the trophoblast cells interact with the epithelial 
cells of the endometrium via surface glycoproteins to adhere the embryo. Adhesion 
molecules, such as integrins and cadherins, bind cells to other cells and also to compounds of 
the extracellular matrix, and therefore play an important role in the anchoring of the embryo 
(Merviel et al., 2001).  
When the embryo is adhered to the endometrium, the trophoblast cells proliferates and 
differentiates into an inner layer of cytotrophoblasts (CT) and outer layer of 
syncytiotrophoblast (ST), as shown in Figure 1.4. The cytotrophoblasts form the inner cell 
layer of mononucleate cells, while the syncytiotrophoblast becomes an external cell layer of 
multinucleate cells facing the maternal tissue. The layer of syncytiotrophoblast subsequently 
invades the endometrium through its production of lytic enzymes and secretion of necessary 
factors. From 9-12 days after conception the blastocyst is deeply implanted and the uterine 
epithelium closes over the implantation site (Baergen and Benirschke, 2010). 
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Figure 1.4: Implantation, day 6-9 (Kaufmann P, 1992). This figure shows the implantation with the 
apposition and adhesion of the blastocyst (day 6-7), following the invasion of the uterine endometrium 
by the syncytiotrophoblast (day 7-8), and the final stage of implantation where the decidua closes 
around the embryo (day 8-9). Small vacuoles, called lacunae, start to form at day 7 to day 9, and 
provides later for the area where the villi are formed. Other cells shown in the figure are the inner 
embryonic cell mass, the outer cytotrophoblastic cells, and the decidual cells of the endometrium.   
 
Upon implantation, the endometrium is modified by a differentiation of maternal cells called 
decidualization. The objective of the decidual reaction is to form a favorable environment for 
the embryo, and the endometrium under pregnancy is now referred to as the decidua. The 
stromal cells
6
 are transformed into decidual cells that produce a large amount of growth 
factors, such as Epidermal Growth Factor (EGF) and Fibroblast Growth Factor (FGF), as well 
as hormones (Prolactin, Renin), and proteins (collagen, laminins), (Healy and Hodgen, 1983). 
The decidua also secretes other factors that inhibit or stimulate the trophoblastic invasion in 
the endometrium to achieve a controlled invasion process. 
The decidua throughout the pregnancy consists of various parts such as the Decidua basalis 
(BD), where the implantation takes place, the Decidua capsularis (CD), that envelopes the 
embryo; and the Decidua parietalis (PD), on the opposite uterus wall (Figure 1.5).  
                                                 
6
 Stromal cells: cells of the connective tissue. 
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Figure 1.5: Decidual membranes (Baergen and Benirschke, 2010). The blue lining constitutes the 
trophoblast of fetal origin, while the decidua of maternal origin is red. Here the three different parts 
of the decidua are shown; The Capsular Decidua (CD), the Basal Decidua (BD) and the Parietal 
Decidua (PD). 
 
1.2.2 Formation of the villi 
During the implantation, small extra-cytoplasmic vacuoles are formed in the 
syncytiotrophoblastic mass to form a system of lacunae which is filled with tissue fluid and 
uterine secretions. The syncytiotrophoblast further invades the area between the lacunae and 
forms the start of the villi; the border between maternal and fetal blood. Subsequently, the 
cytotrophoblast penetrates and invades the syncytiotrophoblast layer forming cellular columns 
called the primary villi (Figure 1.6A).  
At the end of the second week post conception, the implantation phase ends but the invading 
of maternal tissue continues with the forming of the villi.  In the beginning of the third week, 
the cytotrophoblast reaches the trophoblastic shell, the end of the syncytiotrophoblastic layer, 
where it makes physical contact with the endometrium. The secondary villi are formed in the 
middle of the third week, by migration of the mesenchyme
7
 into the primary trophoblast villi 
(Figure 1.6B). At the end of the third week, the tertiary villi are formed by differentiation of 
the mesodermal cells in the core of the villus into blood vessels (Figure 1.6C). This is the 
definitive placental villus and forms the capillary system that later supplies the embryo with 
nutrients and oxygen.  
                                                 
7
 Mesenchyme: Embryonic connective tissue regardless of origin. 
12 
 
 
Figure 1.6: Formation of the villi (Kaufmann P, 1992). Part A (Day 12-15) shows the formation of 
the primary villi between the vacuolar lacunae. The Primary villus consists of the outer layer of 
syncytiotrophoblast and inner layer of cytiotrophoblasts penetrating the outer layer. The secondary 
villi showed in part B (Day 15-21) are formed when the extra-embryonic mesoblast migrates into the 
interior layer of cytotrophoblast. In part C, the tertiary villus is presented with the differentiated fetal 
blood capillaries. 
 
1.2.3 Cytotrophoblast differentiation 
The differentiation of the cytotrophoblast from the implantation stage throughout the 
development of the placenta follows two different roads; either into CT villi or CT extra-villi  
as shown schematic in Figure 1.7. The differentiation of the trophoblastic cells into villous 
phenotype or extravillous phenotype depends on the surrounding environment and contact 
with molecules in the extracellular matrix.   
The CT villi are involved in growth support of the placenta as well as the exchange of 
nutrients and gas between the mother and the fetus, while the CT extra-villi are involved in 
remodeling of arteries and in the anchoring of the placenta (Evain-Brion, 2001). The extra-
villi trophoblast (EVT) cells contain invasive properties and can therefore migrate through the 
decidua in the implantation process. The EVT also develops into giant cells and endovascular 
cells, while the CT-villi fuse into layers of syncytiotrophoblast.  
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Figure 1.7: The two ways of differentiation of human trophoblast (Alsat et al., 1999). 
Cytotrophoblastic stem cells differentiate into either CT extra-villous cells or to CT-villous cells. The 
CT extra-villi are involved in the implantation process, while the CT-villi are supporting the placental 
development. The CT extra-villi proliferate, migrate and invade, and differentiate into giant cells and 
endovascular cells. The CT villi cells fuse together into layers of syncytiotrophoblast.    
 
1.2.4 Invasion of the decidua 
Both during and after the implantation, the cytotrophoblast migrates and invades the maternal 
tissue to form the villous structure. The invasion is a complex process and includes regulated 
degradation of the extracellular matrix (ECM). While invading the maternal tissue, the 
invasive cells encounter various components of the ECM, such as collagen, fibronectin, 
laminin and vitronectin. Cellular secretion of matrix metalloproteinases (MMPs) allows 
degradation of the ECM components so that the cells can migrate through. The matrix 
metalloproteinases MMP-9 and MMP-2, both involved in trophoblast invasion, are 
gelatinases that degrades collagen IV, a major ECM component (Staun-Ram et al., 2004). 
Other invasion mediators are the Tissue Inhibitors of Metalloproteases (TIMPs) that affects 
negatively the invasion.  
 
 
14 
 
In comparison to tumor invasion, the trophoblastic invasion is strictly regulated both in space 
and time. Several other factors than MMPs and TIMPs have been found to have an effect on 
invasion, such as hormones, cytokines and growth factors. The Tumor Necrosis Factor alpha 
(TNFα) was found by Meisser et al. to stimulate invasion by increasing MMP-9 activity 
(Meisser et al., 1999), while the Transforming Growth Factor β (TGFβ) has been showed by 
Graham and Lala to have an inhibiting effect on invasion (Graham and Lala, 1991). This 
controlled invasion is essential in order for the embryo to attach and develop in the uterus, as 
it is part of the stage of placental adhesion where the surfaces of mother and fetus bind to each 
other.  
 
1.2.5 Placental structure at term 
In the fourth month of pregnancy, the placenta takes its definite form. It consists of two 
components; the fetal side and the maternal side. The umbilical cord is located on the fetal 
portion, and the maternal portion is in contact with the endometrium (Figure 1.8).  At the time 
of delivery, the placenta is discoid with a diameter of 15-25 cm, approximately 3 cm thick and 
weighs about 500 g (Sadler, 2012).  
 
Figure 1.8: Anatomy of placenta at term [www.embryology.ch]. The umbilical cord (1) is situated at 
the fetal side of the placenta, while the basal plate (5) is located at the maternal side. The villi (7) are 
the functional elements of the placenta, involved in exhanges between mother and fetus via the 
intervillous space filled with maternal blood (4). The villous structures are grouped into arrangements 
called cotelydons (6). The embryonic part are here shown as the amnion (2) and chronionic part (3). 
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1.3 Factor XIII deficiency and pregnancy  
1.3.1 Factor XIII deficiency 
FXIII deficiency is an autosomal recessive disorder that is caused by homozygote or 
compound heterozygote defects in either the FXIII-A gene or the FXIII-B encoding genes. 
Heterozygote patients can synthesize both wild type and mutant protein, and carriers of the 
disease usually do not develop severe symptoms as a single allele is sufficient to drive the 
synthesis of chains above hampering levels (Hashiguchi and Ichinose, 1995).  
The disorder is usually grouped in FXIII-A deficiency, FXIII-B deficiency and combined 
FXIII-A/FXIII-B deficiency (Ichinose et al., 2005). Most of the reported cases of FXIII 
deficiency are caused by mutations in the FXIII-A subunit where the active enzymatic site is 
located. At the current time, 89 mutations in the FXIII-A gene have been discovered; most of 
them are missense/nonsense or deletion mutations (Human Gene Mutation Database, Institute 
of Medical Genetics in Cardiff, www.hdmd.cf.ac.uk). The FXIII-B subunit is in excess in 
healthy individuals (Kohler et al., 2011), but some few cases of symptoms due to deficiency 
of FXIII-B subunit has been reported (Saito et al., 1990, Ichinose, 2001). Deficiency of 
subunit B usually has milder symptoms than deficiency of subunit A, but can lead to minor 
bleeding tendencies due to the absence of the stabilizing FXIII-B subunit, thus reducing the 
plasma level of FXIII-A.  
The deficiency is not detected in the standard clotting test, since the fibrin fragments form 
blood clots even in the absence of FXIII, but without the crosslinked network which is not 
assessed by thrombin time
8
. A clot formed without FXIII is unstable in weak acids and bases 
and will readily dissolve. Testing of clot stability in 5 M urea have been used to diagnose 
FXIII deficiency (Robbins, 1944), however, this screening test detects only severe FXIII 
deficiency. Kohler et al. recommend a thorough laboratory diagnosis by first measuring the 
plasma FXIII activity, thereafter determining the FXIII-A2B2, FXIII-A and FXIII-B antigen 
concentration (Kohler et al., 2011). Several quantitative assay kits exist commercially, 
amongst other the FDA approved Berichrom FXIII (Dade Behring, Marburg, Germany) 
which measures photometrically the ammonia released in the first step of the transglutaminase 
reaction (Hsieh and Nugent, 2008).   
                                                 
8
 Thrombin time: A blood test that measures the time necessary for forming a clot in excess of 
thrombin.  
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The average plasma concentration of FXIII-A2B2 is 10-20 mg/L and the amount necessary in 
blood to prevent bleeding symptoms is 15% of the average plasma concentration (Bohn et al., 
1973). Management of FXIII deficiency was traditionally treated with cryoprecipitate and 
fresh frozen plasma. Even though successful management of the disorder was obtained with 
this treatment, it included risk of infection by blood borne pathogens and allergic reactions 
and is therefore not recommended (Eshghi et al., 2010). Concentrates of pure plasma FXIII 
are now used instead and are now on the market. Also, a novel trial by Inbal et al. shows that 
recombinant FXIII (rFXIII) can be used safely and efficiently instead of plasma 
supplementation (Inbal et al., 2010).  
 
1.3.2 Involvement of FXIII in pregnancy 
FXIII has been known for several decades to have a role in maintaining pregnancy. The first 
report of a case of FXIII deficiency affecting pregnancy was made by Fisher et al. (1966) 
where a 29-year-old woman had experienced 12 recurrent spontaneous abortions with severe 
uterine bleedings. The woman was diagnosed with FXIII deficiency by investigating the clot 
stability in urea, and treatment was made with plasma transfusions allowing her to carry the 
13
th
 pregnancy to birth to receive a healthy child.  
A study performed by Koseki-Kuno et al. in 2003, showed that the occurring hemorrhage in 
pregnant FXIII-A knockout (KO) mice were of maternal origin by analyzing the location of 
blood pools. The uterine cavity of the KO-mice was filled with blood, but bleeding was not 
observed in the amniotic cavity and fetus region. The same study also detailed that FXIII 
deficient embryos do not contribute to bleeding or miscarriage, as FXIII deficient mice 
embryos developed normally. Thus spontaneous abortions occur only when the maternal 
FXIII is absent; when the mother is healthy, even with a FXIII deficient embryo, the 
pregnancy will be carried to term if no other unrelated complications occur.  
Maternal FXIII is claimed not to be essential before 5-6 weeks after gestation, since abnormal 
decidual bleeding followed by first trimester spontaneous abortion will occur after this period 
if FXIII is absent (Asahina et al., 1998). Although Hsieh and Nugent states in 2008 that 
“massive bleeding associated with microvascular bleeds is no doubt one of the major causes 
of miscarriage and foetal loss in FXIII deficient women”, other plausible theories have been 
considered. Due to the multifunctional nature of FXIII it is not certain that impaired 
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coagulation is the primary cause of abortions caused by nonfunctional maternal FXIII. 
Asahina et al. proposed that FXIII serves as an adhesive protein during the invasion of the 
endometrium by the cytotrophoblast, by promoting the binding between fibronectin receptors 
on cytotrophoblasts and fibronectin produced by stromal fibroblasts (Asahina et al., 1998). 
Fibronectin also binds to type IV collagen located at the surface of decidual cells, as well as 
fibrinogen. These bindings are assumed to strengthen the anchoring of the cytotrophoblasts. 
This theory was developed by showing that decidual Factor XIII is abundantly present at the 
decidual stroma around the invasive cytotrophoblasts at 5 weeks after gestation. No 
localization of FXIII-A was found at 7 weeks after gestation in the decidual stroma, however 
it was found in the mononuclear cells in the decidua. The same study showed that fetal FXIII-
A was found in the Hofbauer cells
9
, see Figure 1.9 for distribution of FXIII-A in the placenta. 
In a later study by Asahina et al. in 2000 it was shown that when the concentration of FXIII-A 
is low, the cytotrophoblastic shell does not form adequately which results in an increased risk 
of abortion due to placental detachment at the Nitabuch’s layer (Figure 1.9). The same authors 
found that FXIII-A was present in the extracellular space of the extravillous cytotrophoblast 
which forms the cytotrophoblastic shell adjacent to the Nitabuch’s layer in normal pregnancy. 
Around poorly formed cytotrophoblastic shells the factor FXIII-A was not detected. 
 
Figure 1.9: Distribution of FXIII-A in the definitive placenta (Muszbek et al., 2011). FXIII-
A containing cellular and structural elements are depicted in purple, including Hofbauer cells 
and the Nitabuch’s fibrinoid layer.  
                                                 
9
 Hofbauer cells: macrophages of embryonic origin. 
18 
 
1.3.3 Aim of study 
In this study, two goals were sought to be achieved, both determination of the location of 
FXIII at the fetal-uterine interphase and also to examine the role of FXIII in maintaining 
pregnancy.  
The complete role of plasma FXIII in maintaining pregnancy is debated, thus the aim of this 
study is to investigate and possibly clarify its’ function in the development of the placenta. 
Our hypothesis is that FXIII could be involved in the control of embryonic invasion in 
maternal tissue by both inducing the crosslinking between the proteins located in the 
extracellular matrix and by forming a network binding the cells to the ECM via integrins and 
cadherins. In this case, the FXIII would impair the invasion, and complete development of the 
placenta will be altered, finally resulting in spontaneous abortion by placental detachment.  
By determination of the origin and role of the FXIII involved in pregnancy we anticipate to 
understand better the physiology of FXIII, specifying the importance of FXIII of uterine, 
plasma or fetal origin. The current management of pregnancy in FXIII deficient women is 
based on a post hoc analysis described in literature; therefore the results would hopefully 
provide guidelines for treatment of FXIII more appropriate to management of pregnancy in 
FXIII deficient women.  
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2. Materials and methods 
 
PART I: Materials 
2.1 Chemicals and materials 
The different chemicals and materials used in this project, as well as their producer and 
catalogue number are listed in Table 2.1.  
Table 2.1: Chemicals used, their manufacturer and catalogue number 
Chemical     Manufacturer  Catalog no. 
 
Acetic acid 96%    CARLO ERBA   302002 
Acrylamide 40%    Eurobio   018803 
Albumin     SIGMA   A-7906 
Ammonium persulfate (APS)   Fluka Biochemika  09917 
Antimouse IgG antibody   Amersham Biosciences   NA931V 
Bisacrylamide 2%    Eurobio   GEPB1200-1 
Bromphenol blue    BIO-RAD   161-0404 
Calcein AM     Interchim   FP895515  
Collagen Type I    BD Biosciences  354236  
Coomassie Brilliant Blue G   SIGMA   B-1131 
Crystal violet     SIGMA   C-3886 
Deoxyribonuclease (Dnase) type IV  SIGMA   D5025-375K 
DMSO      SIGMA   D5879 
F-12 medium     Sigma-aldrich    D2906  
Fetal Calf Serum (FCS)    Gibco Invitrogen  10270-106 
Gelatin Difco     BD Biosciences  214340 
Glycerol     SIGMA   G-7757  
Glycine     Eurobio   GEPGLY00-66 
HANKS’ Balanced salt solution (10x)  Gibco    14185-045 
HEPES      Eurobio   GAUHEP00-64 
Ki67      Dako    F078801 
mAb anti-Factor XIIIa antibody  Novus Biologicals  NB100-696 
Matrigel     BD Biosciences  354234 
2-mercaptoethanol    SIGMA   M6250 
Methanol     Carlo ERBA   309001 
NaCl      Eurobio   GAUNAC01-66 
Nonidet P40 substitue    Amresco   E109-50ML 
NuPage MOPS SDS Running buffer (20x) Invitrogen   NP001 
NuPAGE 10% Bis-Tris Gel 1.5 mm, 10 well  Invitrogen   NP0315BOX 
PBS (10x)     Cambrex   BE17-517Q 
Penicillin G sodium salt   SIGMA   P3032 
Percoll      GE Healthcare   17-5445-02 
Precision Plus Protein All Blue Standard BIO RAD   1610373 
Protein Assay dye reagent concentrate  BIO-RAD   500-0006 
Recombinant human Factor XIIIa (A-subunit) Zedira    T070  
Rb pAb tp Factor XIIIa    Abcam    ab97636 
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Table 2.1: Chemicals used, their manufacturer and catalogue number (continued) 
Chemical     Manufacturer  Catalog no. 
 
RPMI-1640 medium    Sigma-aldrich   R8755 
SDS (10%)     SIGMA   L4522 
Sodium azide     SIGMA   S2002 
Sterile water for irrigation   AGUETTANT   600022 
Streptomycin sulfate salt   SIGMA   S9135 
Temed      Merck    1.10732 
Thincert     Greiner bio-one  662638 
Tris base     SIGMA   T1378 
Triton-X-100     SIGMA   T-8787 
Trypsin      SIGMA   T-4799 
Tween-20     SIGMA   P1379 
Protease inhibitor cocktail   SIGMA   118K412 
 
2.2 Buffers and solutions 
The following recipes were used to prepare various buffers and solutions. The chemicals were 
dissolved in deionized water, unless otherwise stated. Commercially available ready-to-use 
buffers are listed in Table 2.1.  
 
Transfer buffer (1x)      Tris Buffered Saline Tween-20 (1x) 
12.5 mM Tris base     10 mM Tris 
96 mM Glycine      75 mM NaCl 
0.005% SDS      0.05% Tween-20  
10% Methanol      pH was adjusted to 7.6, and  
The buffer was stored at 4°C until use.    the buffer was stored at 4°C until use. 
 
Blocking buffer, milk     Blocking buffer, gelatin  
5% Dry milk in TBS-T (1x)    2.5% Gelatin in TBS-T (1x) 
pH was adjusted to 7.6.     pH was adjusted to  7.6. 
 
Running gel (Zymography)    Stacking gel 
10% Acrylamide     5% Acrylamide 
0.1% Bisacrylamide     0.1% Bisacrylamide 
0.38 M Tris pH 8,8      0.38 M Tris pH 8,8  
0.1% SDS      0.1% SDS 
1 mg/mL Gelatin     0.1% APS 
The solution was heated to dissolve the    0.1% TEMED 
gelatin before adding the APS and TEMED. 
0.1% APS 
0.1% TEMED 
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Laemmli Buffer (2x)     Substrate buffer 
4% SDS       50 mM Tris pH=7.5 
20% Glycerol       0.02% NaN3 
10% β-mercaptoethanol     5 mM CaCl2 
0.004% Bromphenol blue     150 mM NaCl    
0.125 M Tris-HCl 
 
RPMI complete Medium    RPMI-1640 medium (1 L)  
0.02 M HEPES      RPMI 1640 SIGMA powder flask 
100 U/mL penicillin     2g NaHCO3  
0.1 mg/mL streptomycin     pH was adjusted to 7.4 and the medium was 
10% FCS      filtrated (0.2 µm) before storing at 4°C.  
The reagents were mixed and dissolved in        
RPMI-1640 medium and sterile filtered  
(0.2 µm) before use.  
 
F12 complete medium      F-12 Medium (1L)  
100 U/mL penicillin     F-12 SIGMA powder flask 
0.1 mg/mL streptomycin    2.5 g NaHCO3 
10% FCS      pH was adjusted 7.4 and the medium was   
The reagents were mixed and dissolved in   filtrated (0.2 µm) before storing at 4°C.  
F-12 medium and sterile filtered (0.2 µm) 
before use.      
    
Solubilisation buffer     ONC Buffer 
The following was added in the desired   50 mM Tris  
volume of ONC buffer:     120 mM NaCl  
0.1% SDS       1 mM EDTA  
1% Nonidet P40      pH was adjusted to 8 and  
0.5 mM Sodium deoxycholate     the buffer was stored at 4°C. 
1 mM Sodium orthovanedate  
30 mM Β-glycerophosphate  
10 mM NAF  
5 µg/mL Aprotinin 
12.5 µg/mL Leupeptin  
0.1 mg/mL AEBSF      HANKS Buffer (1x) 
       136.7 mM NaCl 
       5.36 mM KCl 
Crystal Violet      0.44 mM KH2PO4 
20 mg Crystal violet was     0.42 mM Na2HPO4     
dissolved in 1 mL of 20% DMSO.    4.16 mM NaHCO3 
The stock solution was stored at    The buffer was sterile filtered  
room temperature and diluted    before used (0.2 µM). 
1:40 with HANKS buffer (1x)  
before usage. 
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Coomassie blue (250 mL)    Decoloration (1L) 
62.5 mg Coomassie brilliant blue   200 mL Methanol  
100 mL Methanol     50 mL Acetic acid  
12.5 mL Acetic acid     25 mL Glycerol  
12.5 mL Glycerol  
 
Bradford      Trypsine 
BIO-RAD Protein assay dye reagent    0.4% Trypsin was dissolved  
concentrate was diluted 1:5 in ionized    in HANKS buffer (1x), then sterile filtered 
water and paper filtered before usage.   (0.2 µm) and freezed until use. 
 
Solution stock A     Digestion solution 
500 ml HBSS      100 mL Solution stock A 
25 mM HEPES      0.1% Trypsin 
4.2 mM MgSO4     Dnase (50 U/mL)  
To be stored at 4°C for 1 month    pH was adjusted to 7.2-7.4 
       and the solution was sterile filtered (0.2 µm). 
 
2.3 Commercial kits 
Commercial kits utilized in the project and their producer is listed in Table 2.2. 
Table 2.2: List over commercial kits 
Name        Producer  Cat no. 
 
5-Bromo-2’deoxy-Uridine labeling and detection kit III  Roche   11444611001 
Supersignal West Pico Chemiluminescent substrate  Thermo Scientific 34080 
   
 
2.4 Apparatus 
The different instruments used and their producer are listed in Table 2.3.  
Table 2.3: List over instruments used and their manufacturer 
Name    Task      Producer  
 
Fusion Fx7   Picturing gels     Vilber Lourmat 
Infinite F200   Absorbance/fluorescence plate reader  Tecan  
 
Ultrospec 3000   Absorbance reader    Pharmacia Biotech 
 
Orbitrap LTQ Velos   Mass spectrometer    Thermoscientific 
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2.5 Tissue collection 
This study was approved by the local ethical committee: “Comités de Protection des 
Personnes”, and informed consent was obtained from each donor before clinical sampling. 
Human placental tissues from the first trimester (7-10 weeks of gestation) were obtained from 
healthy pregnant women from 18 to 43 years old when undergoing voluntary pregnancy 
terminations. 
 
2.6 Cell culture 
The Human Trophoblast cell line (HTR-8/SVneo) line was established by Graham et al. 
(1993) through introducing the gene encoding simian virus 40 large T antigen into first 
trimester human trophoblast HTR-8 cells. The cell line was kindly provided by Dr. Nadia 
Alfaidy (CEA Grenoble, France) in agreement with Dr. Charles Graham. This transfected cell 
line is a model of invasive extravillous trophoblast that shares a number of phenotypic 
properties with the non-transfected parental cells and therefore is an appropriate tool for the 
study of in vitro placental function (Graham et al., 1993). 
In parallel, we preformed the same experiments with extravillous trophoblasts cells extracted 
from first trimester placentas. This primary culture represented a more in vivo approach to 
validate the results obtained with the HTR-8/SVneo cell line.  
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Part II: Methods 
 
2.7 HTR-8/SVneo cell culture 
The human HTR-8/SVneo cell line was cultured at 37°C in an atmosphere of 5% CO2/95% 
air, plated in RPMI 1640 medium supplemented with fetal calf serum (FCS, 10%), HEPES 
(20 mM), penicillin (100 U/mL) and streptomycin (0.1 mg/mL). The cells were grown in 60 
cm
2
 dishes, split with trypsin (0.2%) and not grown beyond 80% confluence. The cells were 
used in invasion assay (Section 2.10) between passage 5 and passage 13. 
  
2.8 Human primary EVT cell isolation 
Human placental tissue was rinsed in cold physiological water and sliced with scalpels. The 
sliced tissue was rinsed three times with physiological water and centrifuged at 200 g for 5 
minutes. Digestion solution (0.1% trypsin in solution A, 50 mL) was added and incubated at 
37°C for 30 minutes without agitation. To stop the tissue degradation, FCS (5 mL) was added. 
After tissue sedimentation, the supernatant was filtered through nylon screen (100 µm) and 
centrifuged at 200 g for 10 min. The cells were washed 4-6 times with warm HBSS (37°C) 
until the wash supernatant was free from extracted cells (controlled by microscopy). The 
supernatants from each wash was pooled, filtered and centrifuged as before. The cell pellets 
were dissolved and pooled in a final volume of 3 mL F12 medium containing FCS (10%) and 
filtered through a nylon screen (40 µm) and layered over a discontinuous Percoll gradient (20-
55%). The gradient was centrifuged for 25 min at 1000 g. The cell layer corresponding to 40-
55% Percoll that contains EVTs was aspired and washed with F12 medium containing FCS 
(10%), thereafter centrifuged at 10 minutes for 200 g. The pellet was dissolved in 100-200 µL 
F12 medium containing FCS (1%) according to size of pellet, and the cell concentration was 
determined with Crystal Violet Cell Counting. Finally, 10
5
 of EVT were incubated per insert 
for the invasion assay (Section 2.10). 
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2.9 Explant cultures 
The wells of a 24-well plate were coated with collagen I diluted in 0.02 M acetic acid (50 
µg/mL, 200 µL). The plate was incubated for one hour at 37°C. The wells were then rinsed 
with sterile physiological water (150 mM NaCl) and air dried.  
Pieces of villous placental tissue (1-2 mm in length and width) from first trimester were 
dissected and placed on the collagen I-coated 24-well plates. The explants were left for 2 
hours at 37°C under 5% CO2 and 95% air atmosphere to permit adhesion of explants to 
collagen, before addition of F12 medium containing FCS (1%), penicillin (100 U/mL) and 
streptomycin (100 µg/mL). After 24 hours the medium was changed to F12 medium 
containing only penicillin (100 U/mL) and streptomycin (100 µg/mL), and the effector was 
added as FXIIIa (50 µg/mL), or FCS (10%). After 24 hours of incubation the conditioned 
medium was collected for substrate gel zymography (Section 2.13) and the tissue explants 
were sent to the laboratory of anatomical pathology at the Poissy Hospital for histological 
proliferation studies (Section 2.12.2).  
 
2.10 In vitro invasion assay 
2.10.1 Principle of invasion assay 
The Boyden chamber assay (Boyden, 1962) is the classical in vitro model used to study cell 
migration. In this project, Thincert culture insert (Greiner bio-one, Frickenhausen, Germany) 
was used, which consists of a porous membrane through which the cells can migrate from the 
upper chamber to the lower compartment (Figure 2.1). The size of the pores (0.8 µm) in the 
membrane is small enough to avoid the passive passage of epithelial and tumor cells, but large 
enough to allow migration. The cells capable of invasion will first degrade the ECM (invasive 
properties) and thereafter migrate through the membrane (migration properties).  
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Figure 2.1: Schematic view of the Thincert principle [www.greinerbioone.com]. The Thincert insert 
consists of a porous membrane (0.8 µm) which is placed in culture plates (24-well plates). 
Extracellular matrix is added on the membrane and allowed to polymerize. The cells are seeded in the 
upper compartment on the matrix together with the effector to study its influence on invasion. The 
system is incubated for a certain amount of time to allow the cells degrade the extracellular matrix in 
order to invade and migrate through the membrane from the upper to the lower chamber. 
   
The membrane is coated with an extracellular matrix for the cells to invade, e.g. matrigel (BD 
Biosciences, San Jose, CA) which contains extracellular matrix proteins such as laminin, 
collagen IV and heparan sulfate proteoglycans (Kleinman et al., 1982). The quantity and 
concentration of matrigel is critical for the assay. A large quantity of matrigel (150-200 
µL/cm
2
) allows the study of the ability to degrade and invade the ECM, and thereafter to 
migrate. However, an overly large quantity may not give the cells sufficient time to invade 
and migrate, and also an excessively high concentration of the matrigel can be too hard to 
invade.  
 
A chemo-attracting effect is obtained by adding medium containing serum in the lower 
chamber. Since FXIII exists in serum, it is necessary to conduct the experiments at 0% FCS in 
the upper chamber. This is unfortunately an unavoidable stress factor for the cells since they 
must live without the necessary growth factors that the serum provides.  
 
To detect the amount of cells that has invaded the ECM and migrated through the membrane, 
the fluorescent dye Calcein-AM (Interchim, Montluçon, France) was used. The dye is 
membrane-permeant and is retained in the cytoplasm of live cells. Inside the cells, the 
Calcein-AM is hydrolyzed by esterase into green fluorescent calcein that can be measured and 
therefore quantify the cell viability. 
27 
 
The invasion assay was used to study the effect of FXIII on both the ability of trophoblast cell 
line and of the primary cultures of extravillous trophoblasts to degrade ECM and both invade 
and migrate through extracellular matrix. Owing to the restricted availability of primary 
human EVTs, extended studies with controls were performed using immortalized extravillous 
trophoblast cell line (HTR-8/SVneo), followed by more limited studies using primary EVTs 
isolated from first trimester placenta to possibly validate the results. 
 
2.10.2 Protocol of invasion assay 
Thincert inserts (Greiner, Frickenhausen, Germany) were coated with BD matrigel (5.05 
mg/mL, 20 µL) and allowed to gel at room temperature for 1.5 hours. Cells (2.8x10
4 
cells/insert for HTR-8/SVneo, and 10
5
 cells/insert for EVT primary culture) in medium (100 
µL) containing 10% FCS were added to the top of the polymerized gel within the insert. 
Medium containing 10% FCS (600 µL) were added to the wells (in the compartment under 
the insert). The thincerts were incubated for 24 hours at 37°C before adding the effector. 
FXIIIa (50 µg/mL), or TNFα (50 ng/ml), dissolved in medium without FCS were added to the 
respective inserts, and the medium in the wells was changed in parallel when adding the 
effectors. The cells were incubated with the effectors for 24 hours. The matrigel and non-
invading cells were removed by a moistened cotton swab, and the insert was washed with 
PBS (1x). Calcein (4 µM, 450 µL) was placed in the lower chamber with the insert, and was 
incubated for 30 min at 37°C. The inserts were washed again in PBS, and thereafter placed in 
wells containing trypsin (0,01%) and incubated at 37°C for 10 minutes with shaking. The 
fluorescence of the trypsin solution containing cells was read twice (2x150 µL) with Infinite 
F200 (Tecan , Männedorf, Switzerland) at λexcitation=485 nm and λemission=535 nm.   
 
2.11 Cytotoxicity test 
Lactate dehydrogenase enzyme activity released into the culture medium was quantified by an 
enzymatic method based on NADH/H
+
 measurement performed by the biochemistry 
laboratory of the Poissy Hospital. The lactate dehydrogenase enzyme is localized in cells and 
its presence in culture medium reflects cellular lysis.     
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2.12 Proliferation 
2.12.1 5-Bromo-2’-deoxy-Uridine labeling 
HTR-8/SVneo cells were seeded in a 96-well culture plate (7.7x10
3 
cells/well) in medium 
containing FCS (10%) and incubated for 24 hours at 37°C at 5% CO2 and 95% air 
atmosphere. After 24 hours, the wells were washed with PBS and FXIIIa was added (50 
µg/mL) in medium without FCS, and FCS (10%) was used as positive control. After 24 hours, 
the protocol of the 5-Bromo-2’-deoxy-Uridine labeling and detection kit III (Roche Applied 
Science, Indianapolis, IN) was followed. In brief, 5-Bromo-2’-deoxy-Uridine (BrdU) was 
added according to kit protocol to each well and incubated for 2 hours. The cells were then 
fixed with a fixing agent containing ethanol at -20°C for 30 minutes. After incubation with 
each reagent of the kit, the wells were washed with PBS. Nuclease was added and incubated 
for 20 min at 37°C without CO2. Anti BrdU was added and incubated 30 minutes at 37°C. 
The substrate was then added and the fluorescence was read with Infinite F200 (Tecan, 
Männedorf, Switzerland) at 405 nm with a λreference=495 nm after 15 minutes.  
 
2.12.2 Immunohistochemistry 
Explants were cultured on collagen as explained in Section 2.9. The explants were fixed for 
24 hours at room temperature in 4% (vol/vol) paraformaldehyde, and embedded in paraffin. 
Histological section (measuring 4 µm in thickness) were deparaffinized and prepared for 
immunohistochemistry by the laboratory of anatomical pathology at the Poissy Hospital. 
Thereafter, the tissue section was incubated with mouse monoclonal anti-Ki67 (Dako, Santa 
Barbara, CA) at 1:60 dilution. Proliferative extravillous trophoblast stained positive as Ki67 is 
a protein of the cellular cycle and therefore the anti-Ki67 functions as a proliferation marker.  
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2.13 Substrate gel zymography 
Conditioned medium mixed with laemmli buffer without mercaptoethanol was deposited (5-
20 µg total protein, quantified by Bradford absorbance measurement, see Section 2.14) on a 
acrylamide gel (10%) containing gelatin (1 mg/mL). Migration was performed at 50 mA/gel. 
The gel was then washed three times in Triton x100 (2,5%) to eliminate SDS, and afterwards 
three times in distilled water. The gel was incubated over night with substrate buffer at 37°C. 
The gel was colored in Coomassie blue for 1 hour, and decolored in decoloration buffer for 2 
hours. The quantification of band intensity was conducted with Bio-1D computer software 
(Vilber Lourmat, France).  
 
2.14 Preparation of protein extracts from placental tissue 
The placental tissue was washed three times with sterile physiological water (4°C), and 
thereafter solubilization buffer was added (300 µL buffer/100 mg tissue). The tissue was 
homogenized with Ultra Turrax (Janke & Kunkel KG, Staufen ik Breishau, Germany) in the 
solubilization buffer five short times to avoid overheating. The homogenized samples were 
left on ice for 1 hour under stirring to allow solubilization. The samples were centrifuged at 
100 000 g for 10 min at 4°C, and the supernatant was recovered as the protein extract. Protein 
extract (1 µL) was mixed with Bradford (800 µL) and incubated for 30 minutes in the dark. 
The absorbance was read at 595 nm (Ultrospec 3000, Pharmacia Biotech, Cambridge, 
United Kingdom) against an albumin standard. After determination of protein concentration, 
the extracts were mixed with one part laemmli buffer and stored at -20°C. 
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2.15 SDS-PAGE gel electrophoresis and western blot 
Precast gels of 10% polyacrylamide (Invitrogen, Karlsruhe, Germany) were used to separate 
proteins by size. The migration was conducted at 200 V for one hour in NuPAGE MOPS SDS 
running buffer. After the electrophoresis, the proteins were transferred to a nitrocellulose 
membrane by electroblotting at 150 V for 1 hour and 30 minutes in 1x Transfer buffer (4°C). 
The membrane was washed with 1x Tris Buffered Saline Tween-20 (TBS-T) and thereafter 
blocked with either 5% milk in TBS-T (1 hour at room temperature with soft stirring) or 2,5% 
gelatin in TBS-T (2 hours at room temperature with soft stirring). Subsequently, an overnight 
incubation with one of two different primary antibodies was performed:  “Antifactor XIIIa 
antibody Mouse” (Novus Biologicals, Littleton, CO) at 1:400 dilution, and “Rb pAb to Factor 
XIIIa” (Abcam, Cambridge, MA) at 1:200 dilution, in respective blocking buffer; milk at 4°C 
or gelatin in room temperature, both with soft stirring.  
The membrane was washed with TBS-T (1x) before incubation with the secondary antibody; 
1:5000 dilution of antimouse IgG (Amersham, Buckinghamshire, UK) diluted in 1x TBS-T, 
for 1 hour at room temperature with soft stirring. Afterwards, the membrane was washed 
again with TBS-T (1x) and detection of the signal was made with ECL supersignal kit 
(Thermo Scientific, Rockford, IL). Visualization of the chemiluminescence was made with 
the Fusion System Fx7 (Vilber Lourmat, France). 
 
2.16 Mass Spectrometry analysis 
A SDS-PAGE gel electrophoresis as described in Section 2.15 was performed, and coloration 
with coomassie blue followed (1 hour coloration, and decoloration overnight). We did the 
following at the proteomic platform of the Jacques Monod Institute in Paris: 
The band with corresponding size was cut out of the gel with a scalpel, and added to a tube 
which contained bicarbonate ammonium solution (50 mM, 100 µL). The gel plugs were 
incubated with shaking for 15 minutes at room temperature. The supernatant was aspirated 
and the step with ammonium bicarbonate solution was repeated. Acetonitrile was added (100 
µL) and incubated for 10 min with shaking at room temperature to dehydrate the plug. Then 
the plug was dried at 37°C for 10 minutes. Dithiothreitol (10 mM, 100 µL) was added to the 
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tube and incubated for 45 min at 56°C with soft shaking. The supernatant was aspired and 
idoacetamide (55 mM, 100 µL) was added, following incubation at 45 minutes at room 
temperature in the dark. The supernatant was aspired and ultra-pure water (100 µL) was 
added to the plug and incubated for 30 minutes with shaking. The water was removed and the 
plug was dehydrated in acetonitrile (100 µL) and incubated for 10 minutes with shaking. The 
plug was dried at 37°C for 10 minutes. Trypsin solution was added (10 ng/µL trypsin in 25 
mM NH4HCO3, 20 µL) at 4°C and incubated for 20 minutes. Afterwards, NH4HCO3 (25 mM, 
10 µL) was added and the plug was incubated overnight at 37°C. The next day, the 
supernatant was transferred to a new tube, and the remaining peptides in the plugs was 
extracted with a solution of acetonitrile (50%) with 0.1% formic acid (20 µL) and incubated 
with soft shaking for 15 minutes. The supernatant was pooled with the preceding supernatant 
and the liquid was allowed to evaporate. The pellet was reconstituted in water with formic 
acid (0.1%, 10 µL). The samples were then analyzed by mass spectrometry in Orbitrap LTQ 
Velos spectrometer (Thermoscientific, Bremen, Germany).  
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3. Results 
  
3.1 Verification of the presence of FXIII in the decidua 
3.1.1 Preliminary results 
A preliminary project was performed at the research laboratory at the Poissy Hospital, with an 
aim to localize and quantitatively measure FXIII mRNA in decidual cells. The localization of 
FXIII was detected in cells that were labeled with a CD14 marker, showing its presence in 
monocytes and macrophages. However it was not detected in cells labeled with a CD56 
marker, demonstrating that FXIII is absent in uterine Natural Killer cells. A genetic paternity 
test was also performed to prove the maternal origin of the FXIII positive cells.   
The quantitative measurement of FXIII mRNA was done by extracting RNA from a biopsy 
sample of the decidua, with tissue verification by morphological analysis, and of a control of 
the placenta at term. The expression of FXIII-A was verified by Real-Time quantitative PCR 
in the decidual sample, and thus showing that FXIII-A is locally synthesized there.   
 
3.1.2 Verification of FXIII localization using immunoblotting 
To verify the presence of the Factor XIII in placental tissue (decidua) of maternal origin, 
protein extracts from placental tissue were separated on a SDS-PAGE gel and immunoblotted 
followed by visualization of bands specific to FXIII-A antibody (Section 2.15).  
Biopsy samples from placental tissue at full term, which contained different types of cells 
from both maternal and fetal origin, were used as control. The decidua samples that were 
studied were protein extracted from decidua at first term, and its maternal origin was verified 
by the pathology service at the Poissy Hospital by morphological analysis.   
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The immunoblotting revealed a band between 75 and 100 kDa (Figure 3.1) that probably 
corresponded to the FXIII-A subunit (83 kDa), suggesting the presence of FXIII-A in the 
decidua. Moreover, this band at 83 kDa appeared more intensively in the placental control 
than in the decidual sample, as described in the literature (Fear et al., 1984). Two other bands 
at 37 kDa were present in the control and the decidual sample. These could correspond to 
isoforms of FXIII-A as a result of posttranscriptional proteolytic processing of the protein; 
this has previously been shown in osteoblast cultures (Al-Jallad et al., 2006) and in bone 
(Nakano et al., 2007). These results were verified by mass spectrometry, see Section 3.1.3. A 
probably non-specific band appeared also at approximately 60 kDa in the control but this was 
not verified by mass spectrometry as it did not appear in the decidual sample.   
 
Figure 3.1: Verification of the presence of FXIII-A in placental tissue by immunoblotting. The size 
of the standard (Std) is shown in kDa at left. The deposited samples are the placental tissue control 
from third trimester (C), and the decidual tissue sample from first trimester (D).   
 
Two different primary antibodies were tested; “Rb pAb to Factor XIIIa” (Abcam, Cambridge, 
MA) and “mAb anti-Factor XIIIa antibody” (Novus Biologicals, Littleton, CO). Both 
antibodies gave the same pattern of bands, but the antibody provided by Novus Biologicals 
was more specific, revealing less unspecific bands. Both blocking in dried milk and gelatin 
were tested, and it was found to give stronger signal and less unspecific bands using milk as 
blocking agent compared to gelatin.  
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3.1.3 Verification of antibody specificity by mass spectrometry 
The same samples used in immunoblotting (Section 3.1.2) were separated by SDS-PAGE gel 
electrophoresis and the bands of interest (~80 kDa and 37 kDa) from Figure 3.1 were 
extracted and processed by mass spectrometry. Table 3.1 shows the identification of FXIII-A 
in the different samples. The score by which the protein was identified is the probability that 
the peptides identified belong to the actual protein. The probability is not expressed in 
percentage since 100% identification is not possible, but a higher score reflects a higher 
probability and also a higher quantity of the peptides in the sample which permits to identify 
the protein.  
The table shows only Factor XIII, but several other proteins were detected, an extract of the 
list is shown in Appendix A. Since the bands at around 83 kDa and 37 kDa were cut out from 
the gel, and no selective immune-precipitation with antibody was conducted, a large amount 
of other proteins of the same molecular weight followed. Also proteins can co-migrate and 
this can explain the detection of proteins with different size, as well as contamination under 
handling can have occurred.   
 
 
Table 3.1: Identity score of Human Blood coagulation Factor XIII-A with different databases 
Database 
Score 
Placenta 37 kDa 
Score 
Placenta 83 kDa 
Score 
Decidua 37 kDa 
Score 
Decidua 83 kDa 
NCBI N.D. 718 N.D. 67 
Swissprot N.D. 756 N.D. 69 
N.D: Not detected 
 
The human coagulation Factor XIII subunit A was detected in both samples extracted from 
the 83 kDa band, but was not detected in the 37 kDa bands, verifying that only the band at 
approximately 83 kDa corresponded to the FXIII-A, and that the 37 kDa was due to 
unspecific binding of antibody.  
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3.2 Study of the role of FXIII in placental development  
3.2.1 Effect of FXIII on invasion of trophoblast 
3.2.1.1 Optimizing of invasion assay  
To study the effect of FXIII on trophoblast invasion, an invasion assay using matrigel was 
performed as explained in Section 2.10. The invasion assay was performed with both cell line 
culture (HTR-8SV/neo) and primary cell culture (extravillous trophoblasts). Before 
examination of the effect of FXIII, the method was tested at different conditions explained in 
the literature (Kilburn et al., 2000, Busch et al., 2009, Kuang et al., 2009, Jovanovic et al., 
2010),  and optimized according to our requirements.  
We tested different concentrations of matrigel (10 mg/mL, 5 mg/mL, 2 mg/mL, 0.5 mg/mL 
and 0.25 mg/mL), as well as the volume of matrigel to be used (20 µL, 30 µL and 100 µL). It 
was found that 5 mg/mL was optimal, corresponding to a 1:2 dilution of the matrigel. A 
volume of 20 µL seemed to be sufficient for testing the invasive properties and was thereafter 
used in the experiments with FXIIIa.  
Following the protocol of the laboratory and different studies on invasion using HTR-
8/SVneo cell line, we chose to work with an initial incubation of cells in the thincert insert, 
before adding effector, to allow attachment and initial proliferation, and thereafter 24 hours of 
incubation with the effector before studying the extent of invasion. We also tested if FXIIIa 
should be added directly in the matrigel when coating the thincert or in the medium 
containing cells added on top of the gelled matrigel. Since no difference was observed, we 
decided to add the effector in the medium containing cells and not in the matrigel.   
Different concentrations of FXIIIa added were also tested in the invasion assay (20 µg/mL, 50 
µg/mL and 100 µg/mL). No dose-dependent effect was observed in the concentration interval 
tested, so we chose to use 50 µg/mL FXIIIa as also used in another study of the effect of 
FXIII on angiogenesis (Dardik et al., 2003).  
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3.2.1.2 Invasion assay using trophoblastic cell line culture 
Five experiments with the optimal conditions of the assay were completed with the HTR-
8/SVneo cell line. In the experiments, FCS was used as a positive control but it showed great 
variability and was therefore excluded from the results. In the two last experiments, the TNFα 
was included as a positive control, but showed no effect on the invasion in our study. Raw 
data and calculations are given in Appendix B, and the results are shown in Figure 3.2, where 
a negative effect on invasion can be observed for FXIIIa compared to the control with no 
effector or serum added.  
 
 
Figure 3.2 Effect of FXIIIa on trophoblast invasion relative to control using HTR-8/SVneo cell 
line. Cells were incubated in presence of FXIIIa or TNFα, or without effector (control) during 24 
hours in the invasion assay. The negative effect of FXIIIa was found to be significant (p=0.0313, *). 
 
The calculated effect of FXIIIa was found to be 45% ± 13% inhibition on the invasion of 
HTR-8/SVneo cells. Statistical analysis was performed using the software GraphPad Instat 
(Graphpad software Inc., San Diego, CA) and the effect was found to be significant by the 
one-tailed non-parametric Wilcoxon test (p=0.0313).   
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3.2.1.3 Invasion assay using trophoblastic primary culture 
Ten experiments were conducted to study the effect of FXIIIa on trophoblast invasion using 
primary culture of EVT cells. Only control (without effector) and FXIIIa (50 µg/mL) was 
studied due to scarce access to EVT cells. The raw data and calculations are available in 
Appendix B. The results are shown in Figure 3.3 where no effect is observed compared to the 
control.  
 
Figure 3.3 Effect of FXIIIa on trophoblast invasion relative to control using primary culture of 
extravillous trophoblast cells. The primary culture cells were incubated without (control) or with 
effector (FXIIIa) during 24 hours in the invasion assay. 
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3.2.2 Effect of FXIII on secretion of matrix metalloproteases 
Substrate gel zymography was used to measure the gelatinase activity of secreted matrix 
metalloproteases MMP-9 and MMP-2, in conditioned medium of cell culture invasion assays 
and explants attached to collagen. Figure 3.4 shows a representative secretion pattern of 
MMP-9 and MMP-2 at 92 kDa and 72 kDa respectively.  
  
Figure 3.4: Representative secretion pattern of matrix metalloprotease activity. The MMP-9 (92 
kDa) and MMP-2 (72 kDa) secretion were examined with substrate gel zymography. The control was 
treated the same way as the FXIIIa sample, but without the addition of the effector.  
 
Each band was quantified with the Bio-1D software (Vilber Lourmat, France), for both MMP-
9 and MMP-2. For raw data and calculations, see Appendix C. The result for each system; the 
HTR-8/SVneo cell line, EVT primary culture and the explants; regarding both MMP-9 and 
MMP-2, is shown respectively in Figure 3.5 and 3.6. The effect of each system studied on 
both MMP-9 and MMP-2 was found to be not significant with statistical analysis using a two-
tailed non-parametric Wilcoxon test, with the software GraphPad Instat (data not shown). 
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Figure 3.5 Effect of FXIIIa on MMP-9 secretion relative to control. Substrate gel zymography was 
used to study the change in matrix metalloprotease activity in presence of FXIIIa in three different 
systems: HTR-8/SVneo cell line (HTR), extravillous trophoblast primary culture (EVT), and explants.  
 
 
 
Figure 3.6 Effect of FXIIIa on MMP-2 secretion relative to control. Substrate gel zymography was 
used to study the change in matrix metalloprotease activity in presence of FXIIIa in three different 
systems: HTR-8/SVneo cell line (HTR), extravillous trophoblast primary culture (EVT), and explants. 
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3.2.3 Effect of FXIII on proliferation 
 
3.2.3.1 Proliferation in HTR-8/SVneo cell line by BrdU incorporation 
Proliferation studies of the effect of FXIIIa on the HTR-8/SVneo cell line were performed 
three times by using BrdU incorporation. A test of increasing cell amount (from 2.5x10
3
 to 
1x10
5
 cells) was performed and it was found that a dose of 7.7x10
3
 cells/well was suitable as 
shown in Appendix D. Using this condition there was no observed effect of FXIII on 
proliferation (data not shown). However, no proliferation was observed in the cells with added 
serum either, which renders the results obtained for FXIIIa by this method unreliable. 
 
3.2.3.2 Proliferation in explants by immunohistochemistry analysis 
Another method for proliferation was performed with explants attached to collagen. After 24 
hours incubation with/without effector, the explants were transferred for 
immunohistochemistry analysis as described in Section 2.9 and 2.12.2. The proliferative 
nuclei (marked with anti-Ki67) were counted by the software ImageJ (National institutes of 
Health, Bethesda, MD) and divided by the measured surface ratio of the tissue to obtain a 
comparable quantity between the samples. Three representative photographs are shown in 
Figure 3.7, where the proliferation in control tissue (A) and tissue treated with FXIIIa (B) is 
approximately the same, while the tissue treated with 10% FCS (C) shows an increased 
amount of nuclei in a state of proliferation. The non-treated control tissue shows 
approximately the same extent of proliferation as the tissue treated with FXIIIa, compared to 
the increased proliferation observed in tissue treated with serum (10% FCS). 
 
Figure 3.7: Proliferation study in explant using Ki67 marking. Three representative microscopy 
photographs (100x magnification) of non-treated control tissue (A), tissue treated with FXIIIa (B), and 
tissue treated with 10% FCS (C) are shown.   
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The effect of FXIIIa was compared to the control without effector and to the positive control 
with FCS (10%). The results are shown in Figure 3.8, where no effect of FXIII is observed. 
The effect of added serum shows a slight effect on proliferation as expected, however this 
effect was not found significant by a two tailed Wilcoxon test (p=0.1563). 
 
Figure 3.8: Proliferation effect of FXIII and serum on explants relative to control. The effect of 
FXIIIa on proliferation was studied with anti-Ki67 marking. The control was treated the same way as 
the explants with added effectors (FXIIIa and FCS 10%) but without serum or effector added.  
 
3.2.5 Effect of FXIII on cytotoxicity 
No cytotoxicity was observed with the various effectors tested as the lactate dehydrogenase 
level was not elevated in the conditioned medium (data not shown). 
 
 
 
 
 
 
 
 
42 
 
4. Discussion 
 
4.1 Localization of FXIII 
FXIII is already known to be located in monocyte-derived tissue macrophages in the placenta 
(Adány et al., 1988) and in the uterus (Adány and Muszbek, 1989). According to Adány and 
Muszbek, the presence of FXIII-A in the uterus is however not characteristic for the uterus, 
but for the monocyte/macrophage cell line including tissue macrophages in general. 
  
Asahina et al. (2000) hypothesized that the level of maternal plasma FXIII-A is the most 
important for maintaining pregnancy, and not the cellular concentration, which would mean 
that the FXIII-A necessary for pregnancy is transported to the site of action by blood. This 
theory is well supported by the fact that blood supplementation throughout the pregnancy in a 
FXIII deficient woman is sufficient to carry the pregnancy to term.  
 
In our study, FXIII-A was consistently found in the decidua from first term placenta by 
immunoblotting with antibody specific to FXIII-A, which supports the preliminary results 
obtained at the same laboratory where FXIII-A was found to be locally synthesized in the 
decidua. Therefore, we believe its presence and role in the placenta under development is not 
solely a result of transport from the blood circulation.  
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4.2 Role of FXIII in pregnancy 
FXIII deficient patients experience recurrent pregnancy loss without replacement therapy. The 
fact that blood substitution of FXIII is sufficient to maintain the pregnancy proves the primary 
importance of plasma FXIII (Padmanabhan et al., 2004, Asahina et al., 2007, Ichinose et al., 
2005). The role of cellular FXIII found in the macrophages of the decidua remains unclear.  
Earlier it was believed that FXIII solely prevented severe decidual bleeding due to its role in 
blood clotting, as massive bleeding and following spontaneous abortion was the outcome in 
FXIII deficient pregnant patients. However, FXIII-A seems to have a non-coagulation related 
role by stabilizing of the fibrin layer at the fetal-uterine interface. According to Kobayashi et 
al. (1999), FXIII  in macrophages may play a role in assisting the feto-maternal adhesion, 
attaching cells and extracellular matrix together. This can be achieved by crosslinking 
adhesive proteins, such as fibrinogen, fibrin and collagen.   
We also believe that FXIII affects the trophoblast invasion during placental development, by 
crosslinking extracellular matrix proteins, and therefore also assisting in cell attachment to the 
extracellular matrix. Our hypothesis is that this attachment may hinder the cells from invading 
the maternal tissue. Thus, it is believed that FXIII controls invasion in an indirect way 
through cell adhesion. This may support the theory that FXIII is involved in anchoring of the 
placenta, but it remains to explore the mechanism of cell adhesion to a higher extent.  
It was found in this study that FXIII asserts an inhibiting effect on the invasion using the 
HTR-8/SVneo trophoblastic cell line, but no effect was observed in the primary culture of 
extravillous trophoblastic cells. When using the EVT cells, we experienced problems with the 
blank samples (without cells) giving higher reading values than the samples with cells. The 
calculations were performed without retiring the blank values, thus the reliability of the 
results is in question. If the indecisive values obtained are due to problems with the invasion 
assay and the conditions used, either more optimizing of the technique or an another method 
needs to be considered. For the moment the laboratory is trying a new method, using DAPI-
coloration of the cells and thereby counting the cells that have migrated through the 
membrane manually. It remains to be verified if this method is more reliable than the invasion 
assay using fluorescent calcein. 
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Explanations for the large variability observed in the results from the invasion studies with 
primary culture, could be due to that the primary culture cells were extracted from abortion 
products at different stages in pregnancy (7-10 weeks of gestation) and also that the 
termination of pregnancy was caused by both medicament treatment and suction abortion. 
Correlations between the results and the differences explained here were regarded, but no 
connection was found.  
Also, the question of using EVT cells to study the effect of FXIII on invasion must be 
regarded. FXIII is found to be located in the Nitabuch’s layer, and possibly the EVT cells are 
located further away from this layer, thus maybe not affecting the invasion to such a great 
extent. When studying an invasion model composed of explants instead, the whole range of 
cells involved in placental development can be examined.  
Other factors that might affect the in vivo in contrast to the in vitro system could be the fact 
that oxygen is present during the experiments where cells come from 7-10 weeks placenta, 
while in fact under the placental development there is hypoxia until the 11
th
 week of gestation 
(Schneider, 2011).    
Both BrdU incorporation and Ki67 marking were used to verify that the effect observed on 
invasion by the trophoblastic cell line was not caused by an effect on proliferation. The BrdU 
incorporation in the HTR-8/SVneo cell line showed no effect of FXIII on proliferation, but no 
effect of added serum either, which renders the results unreliable. It remains to verify the 
result by either optimizing the method or by using another technique, for instance a standard 
cell counting. The Ki67 marking showed no effect on proliferation when FXIII was added to 
explants, and an increase in proliferation, though non-significant by statistical analysis, was 
observed when serum was added. However, this verification of absence of effect on 
proliferation was made only on explants, and it remains to verify the same result using a 
trophoblastic cell line. 
Regarding the secretion of matrix metalloproteases, no effect was observed in the 
trophoblastic cell line, primary cultures or explants. This shows that the possible effect on cell 
invasion by FXIII is not due to altered secretion of matrix metalloproteases, and thus may 
imply that the effect is solely caused by cell and protein adhesion. Even though no effect was 
observed in the pilot studies, it remains to include controls known for their effect on secretion 
of MMPs to be more certain of our conclusions.   
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4.3 Controls 
Serum (10% FCS) was tested as a control in this project, both for invasion, proliferation and 
examination of secretion of MMPs. Due to large variability in the results obtained, it was 
concluded that the serum is not an optimal control. The large variability and low 
reproducibility might be due to differences in content of different batches of serum, as well as 
the fact that serum contains a vast amount of different molecules. A more reliable control 
would be a single molecule that is used in the same way as FXIII, proven to have an effect on 
invasion and secretion of MMPs, e.g. TNFα. In the two last experiments of invasion using the 
HTR-8/SVneo cell line, TNFα was included. Unfortunately, it was discovered later that the 
reported effect of TNFα is somewhat ambiguous. Meisser et al. found a proinvasive outcome 
by presence of TNFα (Meisser et al., 1999), but lately there has been reported an inhibiting 
effect of TNFα on invasion (Xu et al., 2011, Otun et al., 2011). This makes TNFα not an 
optimal control either. Thus, it remains to find a better control to validate the results obtained. 
Regarding a negative control, it was found in the literature that FXIIIa could be inactivated by 
treatment with iodoacetamide, an inhibitor of transglutamination. It could therefore be a 
promising negative control to compare the values obtained of inhibited FXIII versus active 
FXIII (Dardik et al., 2003).   
 
 
 
 
 
 
 
 
  
46 
 
5. Conclusion and perspectives 
 
Exploring the effect of FXIII on invasion needs further work, both concerning excluding the 
possibility that the effect observed with the in vitro system is due to proliferation or apoptosis 
events, and finding a system approaching in vivo conditions supporting these results. In order 
to verify the results obtained, functional controls need to be included, and also it would be 
interesting to block the function of FXIII and compare the results obtained from the 
inhibition.   
It is also interesting to study the effect of FXIIIa on gene expression by microarray, and RNA 
extraction of explants used in the experiments in this study is ongoing. FXIIIa is likely to 
require adaptive changes in the cell that needs modifications of gene expression. Altering of 
gene expression might give indirect information about the processes involving FXIII.     
Further on, it is desirable to explore the molecules involved in crosslinking that FXIII may 
induce during placental development. A method for studying this might be to extract proteins 
from the matrigel containing cells, after addition of FXIIIa. An immunoprecipitation of the 
protein extract with an antibody directed against N-epsilon (γ-L glutamyl)-L-lysine isopeptide 
can be used to select the proteins crosslinked by FXIII. Hopefully, this could identify the 
molecules involved in the crosslinking and thereby increase our knowledge of the role of 
FXIII in placental development.     
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Appendix A: Mass spectrometry results  
 
Two different protein extracts (placental and decidual extract) were separated by size with gel 
electrophoresis. Two bands were cut out from each sample: the 37 kDa band (A) and the 83 
kDa band (B) from the placental sample, and the 37 kDa band (C) and the 83 kDa band (D) 
from the decidual sample. An extract of the list obtained from mass spectrometry analysis of 
some of the proteins identified from the NCBI database and the Swissprot database are shown 
respectively in Table A.1 and Table A.2. The factor XIII-A identified is marked in yellow. 
The score by which the protein was identified is the probability that the peptides identified 
belong to the actual protein. The probability is not expressed in percentage since the 100% 
identification is not possible, but a higher score reflects a higher probability and also a higher 
quantity of the protein in the sample.  
 
Table A.1: List of proteins identified with the NCBI database 
Accession Description 
Score 
A 
Score 
B 
Score 
C 
Score 
D 
MW 
[kDa] 
calc. 
pI 
154146191 
heat shock protein HSP 90-alpha 
isoform 2 [Homo sapiens] 
N.D. 2883.6 49.7 2125.5 84.6 5.0 
20149594 
heat shock protein HSP 90-beta 
[Homo sapiens] 
N.D. 2770.2 N.D. 2560.8 83.2 5.0 
190026 plasminogen [Homo sapiens] N.D. 1277.0 N.D. 196.7 90.5 7.2 
20072188 
Aconitase 2, mitochondrial [Homo 
sapiens] 
N.D. 1238.7 N.D. 1336.7 85.5 7.7 
221045102 
unnamed protein product [Homo 
sapiens] 
N.D. 1235.5 N.D. 1924.6 78.8 6.1 
62020522 Glucosidase I [Homo sapiens] N.D. 933.9 N.D. 180.9 91.8 9.0 
154354966 
mitochondrial inner membrane 
protein isoform 3 [Homo sapiens] 
N.D. 866.1 N.D. 257.9 82.6 6.6 
12053275 hypothetical protein [Homo sapiens] N.D. 844.7 N.D. 773.0 91.7 5.5 
168988718 
Chain A, Structure Of Human Serum 
Albumin With S-Naproxen And The 
Ga Module 
612.0 828.0 944.5 1578.6 65.8 5.9 
119620058 
glucosidase I, isoform CRA_a [Homo 
sapiens] 
N.D. 820.0 N.D. 180.9 74.3 6.9 
154354962 
mitochondrial inner membrane 
protein isoform 2 [Homo sapiens] 
N.D. 806.3 N.D. 230.2 83.5 6.6 
1127268 
Chain A, Three-Dimensional 
Structure Of A Transglutaminase: 
Human Blood Coagulation Factor Xiii 
N.D. 717.9 N.D. 67.5 83.1 6.0 
11935049 keratin 1 [Homo sapiens] 581.6 695.5 899.1 63.8 66.0 8.1 
153217289 
Complement component 4A 
(Rodgers blood group) [Homo 
sapiens] 
N.D. 671.3 N.D. 607.2 192.7 7.1 
A: Placental sample 37 kDa, B: Placental sample 83 kDa, C: Decidual sample 37 kDa,  
D: Decidual sample 83 kDa, MW: molecular weight, calc. pI: calculated pI, N.D.: Not detected. 
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Tabel A.2: List of proteins identified with the Swissprot database 
Accession 
 
Description 
Score 
A 
Score 
B 
Score 
C 
Score 
D 
MW 
[kDa] 
calc. 
pI 
P07900 
Heat shock protein HSP 90-alpha 
OS=Homo sapiens GN=HSP90AA1 
PE=1 SV=5 - [HS90A_HUMAN] 
N.D. 3153.4 49.7 2267.1 84.6 5.0 
P08238 
Heat shock protein HSP 90-beta 
OS=Homo sapiens GN=HSP90AB1 
PE=1 SV=4 - [HS90B_HUMAN] 
N.D. 2969.6 N.D. 2704.0 83.2 5.0 
P00747 
Plasminogen OS=Homo sapiens 
GN=PLG PE=1 SV=2 - 
[PLMN_HUMAN] 
N.D. 1335.4 N.D. 185.9 90.5 7.2 
Q99798 
Aconitate hydratase, mitochondrial 
OS=Homo sapiens GN=ACO2 PE=1 
SV=2 - [ACON_HUMAN] 
N.D. 1287.2 N.D. 1341.4 85.4 7.6 
P06396 
Gelsolin OS=Homo sapiens 
GN=GSN PE=1 SV=1 - 
[GELS_HUMAN] 
N.D. 1279.4 N.D. 1949.1 85.6 6.3 
Q13724 
Mannosyl-oligosaccharide 
glucosidase OS=Homo sapiens 
GN=MOGS PE=1 SV=5 - 
[MOGS_HUMAN] 
N.D. 1011.8 N.D. 196.6 91.9 8.9 
P02786 
Transferrin receptor protein 1 
OS=Homo sapiens GN=TFRC PE=1 
SV=2 - [TFR1_HUMAN] 
N.D. 918.3 N.D. 211.0 84.8 6.6 
Q16891 
Mitochondrial inner membrane 
protein OS=Homo sapiens 
GN=IMMT PE=1 SV=1 - 
[IMMT_HUMAN] 
N.D. 890.9 N.D. 278.0 83.6 6.5 
Q96QK1 
Vacuolar protein sorting-associated 
protein 35 OS=Homo sapiens 
GN=VPS35 PE=1 SV=2 - 
[VPS35_HUMAN] 
N.D. 880.6 N.D. 798.6 91.6 5.5 
P02768 
Serum albumin OS=Homo sapiens 
GN=ALB PE=1 SV=2 - 
[ALBU_HUMAN] 
654.3 863.8 996.3 1641.6 69.3 6.3 
P00488 
Coagulation factor XIII A chain 
OS=Homo sapiens GN=F13A1 
PE=1 SV=4 - [F13A_HUMAN] 
N.D. 756.4 N.D. 69.4 83.2 6.1 
P35222 
Catenin beta-1 OS=Homo sapiens 
GN=CTNNB1 PE=1 SV=1 - 
[CTNB1_HUMAN] 
N.D. 731.1 N.D. 150.2 85.4 5.9 
P04264 
Keratin, type II cytoskeletal 1 
OS=Homo sapiens GN=KRT1 PE=1 
SV=6 - [K2C1_HUMAN] 
617.1 722.9 952.1 63.8 66.0 8.1 
A: Placental sample 37 kDa, B: Placental sample 83 kDa, C: Decidual sample 37 kDa,  
D: Decidual sample 83 kDa, MW: molecular weight, calc. pI: calculated pI, N.D.: Not detected. 
 
List of peptides detected corresponding to the FXIII-A from the NCBI database and the 
Swissprot database are shown in Table A.3 and A.4, respectively.   
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Table A.3: Detection of peptides belonging to FXIII-A, identified with the NCBI database 
Sequence 
Protein Group 
Accessions 
A B C D 
QIGGDGMMDITDTYK 1127268 N.D. High N.D. N.D. 
QIGGDGMMDITDTYK 1127268 N.D. High N.D. N.D. 
SNVDMDFEVENAVLGK 1127268 N.D. High N.D. N.D. 
GTYIPVPIVSELQSGK 1127268;194385606 N.D. High N.D. N.D. 
LALETALMYGAK 1127268;194385606 N.D. High N.D. N.D. 
STVLTIPEIIIK 1127268;194385606 N.D. High N.D. N.D. 
MYVAVWTPYGVLR 1127268;194385606 N.D. High N.D. N.D. 
QIGGDGMMDITDTYK 1127268 N.D. High N.D. N.D. 
KPLNTEGVMK 1127268;194385606 N.D. High N.D. N.D. 
LIASMSSDSLR 1127268;194385606 N.D. High N.D. N.D. 
FQEGQEEER 1127268;194385606 N.D. High N.D. Medium 
MYVAVWTPYGVLR 1127268;194385606 N.D. High N.D. N.D. 
DGTHVVENVDATHIGK 1127268;194385606 N.D. Medium N.D. N.D. 
EIRPNSTVQWEEVCRPWVSGHR 1127268 N.D. Medium N.D. N.D. 
VGSAMVNAK 1127268;194385606 N.D. Medium N.D. High 
KPLNTEGVMK 1127268;194385606 N.D. Low N.D. Low 
LSIQSSPK 1127268;194385606 N.D. Low N.D. Medium 
KDGTHVVENVDATHIGK 1127268;194385606 N.D. Low N.D. N.D. 
WDTNKVDHHTDKYENNK 1127268;194385606 N.D. Low N.D. N.D. 
VDHHTDKYENNK 1127268;194385606 N.D. Low N.D. N.D. 
A: Placental sample 37 kDa, B: Placental sample 83 kDa, C: Decidual sample 37 kDa,  
D: Decidual sample 83 kDa, N.D.: Not detected. 
 
Table A.4: Detection of peptides belonging to FXIII-A, identified with Swissprot database 
Sequence Protein Group Accessions A B C D 
QIGGDGMMDITDTYK P00488 N.D. High N.D. N.D. 
QIGGDGMMDITDTYK P00488 N.D. High N.D. N.D. 
SNVDMDFEVENAVLGK P00488 N.D. High N.D. N.D. 
GTYIPVPIVSELQSGK P00488 N.D. High N.D. N.D. 
LALETALMYGAK P00488 N.D. High N.D. N.D. 
STVLTIPEIIIK P00488 N.D. High N.D. N.D. 
MYVAVWTPYGVLR P00488 N.D. High N.D. N.D. 
QIGGDGMMDITDTYK P00488 N.D. High N.D. N.D. 
KPLNTEGVMK P00488 N.D. High N.D. N.D. 
LIASMSSDSLR P00488 N.D. High N.D. N.D. 
FQEGQEEER P00488 N.D. High N.D. High 
MYVAVWTPYGVLR P00488 N.D. High N.D. N.D. 
DGTHVVENVDATHIGK P00488 N.D. High N.D. N.D. 
EIRPNSTVQWEEVCRPWVSGHR P00488 N.D. High N.D. N.D. 
VGSAMVNAK P00488 N.D. High N.D. High 
KPLNTEGVMK P00488 N.D. Medium N.D. Low 
LSIQSSPK P00488 N.D. Medium N.D. High 
KDGTHVVENVDATHIGK P00488 N.D. Medium N.D. N.D. 
WDTNKVDHHTDKYENNK P00488 N.D. Medium N.D. N.D. 
VDHHTDKYENNK P00488 N.D. Low N.D. N.D. 
A: Placental sample 37 kDa, B: Placental sample 83 kDa, C: Decidual sample 37 kDa,  
D: Decidual sample 83 kDa, N.D.: Not detected. 
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Appendix B: Raw data from invasion studies 
 
B.1 Cell line Invasion Assay 
The raw data obtained from the invasion assay using the trophoblastic cell line is given in 
Table B.1-B.5 respectively for each of the five different experiments performed. The parallel 
1 and 2 are fluorescent measurements done twice of the same sample. In experiment 2-5 
triplicates of each sample were performed (a-b-c).  
The calculation of the effect was conducted using equations shown in equation B.1, standard 
deviation in equation B.2 and the standard error of mean (S.E.M) in B.3, where σ is standard 
deviation, N is number of experiments,    is value of sample i, and  ̅ is the average value. 
The net value was calculated by subtracting the blank value (without cells) from the measured 
fluorescent value of each sample. 
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    √
 
 
∑      ̅  
 
        (B.2) 
        
 
 
       (B.3)  
 
Table B.1: Fluorescent readings of samples from invasion assay no. 1  
Conditions Parallel 1 Parallel 2 Average Net value Effect 
Blank  11359 12250 11805 - - 
FCS (10%) 16186 19869 18028 6223 0.25 
Control (FCS 0%) 36899 37096 36998 25193 1 
FXIIIa (50 µg/mL) 20922 23212 22067 10263 0.41 
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Table B.2: Fluorescent readings of samples from invasion assay no. 2 
Conditions Parallel 1 Parallel 2 Average Net value Effect 
Blank – a 19996 20413 
21123 
- 
 
- Blank – b 22364 21076 
Blank – c 21180 21708 
FCS (10%) – a 39087 38794 
32456 11333 1.72 FCS (10%) – b 33532 33285 
FCS (10%) – c  25140 24898 
Control (FCS 0%) – a 26986 26819 
27702 6580 1 Control (FCS 0%) – b 27996 27691 
Control (FCS 0%) – c 28102 28620 
F13a (50 µg/mL) – a 23589 24185 
22558 1435 0.22 F13a (50 µg/mL) – b 19841 20248 
F13a (50 µg/mL) – c 23058 24426 
 
Table B.3: Fluorescent readings of samples from invasion assay no. 3 
Conditions Parallel 1 Parallel 2 Average Net value Effect 
Blank – a 334 328 
348 - - Blank – b 317 307 
Blank – c 411 391 
FCS (10%) – a 819 888 
693 345 0.55 FCS (10%) – b 538 526 
FCS (10%) – c  - - 
Control (FCS 0%) – a 1477 1126 
973 625 1 Control (FCS 0%) – b 850 817 
Control (FCS 0%) – c 758 811 
FXIIIa (50 µg/mL) – a 674 634 
869 387 0.62 FXIIIa (50 µg/mL) – b 771 859 
FXIIIa (50 µg/mL) – c 1037 1242 
TNFα (50 ng/mL) – a 1086 1136 
1086 738 1.18 TNFα (50 ng/mL) – b 1035 - 
TNFα (50 ng/mL)  – c - - 
 
 
 
 
 
 
 
 
 
III 
 
Table B.4: Fluorescent readings of samples from invasion assay no. 4 
Conditions Parallel 1 Parallel 2 Average Net value Effect 
Blank  – a 20686 22141 
24174 - - Blank – b 23463 24278 
Blank – c 27430 27048 
FCS (10%) – a 18710 18826 
26278 2104 0.47 FCS (10%) – b 32118 32731 
FCS (10%) – c  27319 27964 
Control (FCS 0%) – a 28203 28386 
28696 4522 1 Control (FCS 0%) – b 21340 21688 
Control (FCS 0%) – c 43017 44204 
FXIIIa (50 µg/mL) – a 21072 21657 
 
28298 
 
4124 
 
0.91 
FXIIIa (50 µg/mL) – b 30689 30493 
FXIIIa (50 µg/mL) – c 24099 25089 
TNFα (50 ng/mL)  – a 33231 33304 
26733 2559 0.57 TNFα (50 ng/mL) – b 24414 25064 
TNFα (50 ng/mL) – c 29612 29977 
 
Table B.5: Fluorescent readings of samples from invasion assay no. 5 
Conditions Parallel 1 Parallel 2 Average Net value Effect 
Blank – a 14953 15127 
14532 
    
Blank – b 13447 13498 
Blank – c 15083 15082 
FCS (10%) – a 18411 18380 
17387 2855 0.16 FCS (10%) – b 14413 14659 
FCS (10%) – c  19292 19165 
Control (FCS 0%) – a 40947 37545 
32663 18132 1 Control (FCS 0%) – b 30013 30122 
Control (FCS 0%) – c 36957 37344 
FXIIIa (50 µg/mL) – a 24059 24319 
 
24866 
 
10335 
 
0.57 
FXIIIa (50 µg/mL) – b 31171 30216 
FXIIIa (50 µg/mL) – c 20711 21515 
TNFα (50 ng/mL) – a 29444 28786 
24280 9749 0.54 TNFα (50 ng/mL) – b 18039 19048 
TNFα (50 ng/mL) – c 16229 16081 
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Summary of effects and calculated average, standard deviation and standard error of mean of 
the invasion assays performed using the trophoblastic cell line are shown in Table B.6. 
 
Table B.6: Summary of invasion assay using trophoblastic cell line  
Experiment Control  
(0% FCS) 
FXIIIa 
(50 µg/mL) 
FCS 
(10%) 
TNFα 
(50 ng/mL) 
1 1 0.41 0.25 - 
2 1 0.22 1.72 - 
3 1 0.62 0.55 1.18 
4 1 0.57 0.15 1.40 
5 1 0.91 0.47 0.57 
Average 1 0.55 0.63 1.05 
Standard deviation - 
 0.26 0.63 0.16 
SEM - 0.13 0.32 0.11 
 
 
B.2 Primary culture invasion assay 
The raw data obtained for the ten times we did the invasion assay using extravillous 
trophoblast primary culture are given in Table B.7. The parallels 1 and 2 are fluorescent 
measurements done twice of the same sample. In experiment no. 2, duplicates of samples 
were conducted (a-b), however, due to scarce access of primary culture cells only singular 
samples were made in the other experiments. The calculation of the effect was conducted as 
the same way explained in Section B.1. 
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Table B.7: Fluorescent readings of invasion assay 1-10 with primary culture cells 
Experiment Conditions Parallel 1 Parallel 2 Average 
1 
Control (0% FCS) 41131 42412 41772 
FXIIIa (50 µg/mL) 34456 34779 34618 
2 
Control (0% FCS) – a 20159 20622 
21301 
Control (0% FCS) – b 22075 22347 
FXIIIa  (50 µg/mL) – a 18504 18683 
17783 
FXIIIa (50 µg/mL)  – b 16756 17189 
3 
 
Control (0% FCS) 41378 43942 42660 
FXIIIa (50 µg/mL) 32010 32934 32472 
4 
 
Control (0% FCS) 40990 42045 41518 
FXIIIa (50 µg/mL) 33511 34424 33968 
5 
Control (0% FCS) 16585 16838 
15914 
Control (0% FCS) 14985 15247 
FXIIIa (50 µg/mL) 23585 23344 
20203 
FXIIIa (50 µg/mL) 16807 17077 
6 
Control (0% FCS) 32859 32800 32830 
FXIIIa (50 µg/mL) 35245 35482 35364 
7 
Control (0% FCS) 33039 33213 33126 
FXIIIa (50 µg/mL) 42016 41898 41957 
8 
Control (0% FCS) 14991 15034 15013 
FXIIIa (50 µg/mL) 16025 16445 16235 
9 
Control (0% FCS) 30008 29835 29922 
FXIIIa (50 µg/mL) 42483 42786 42635 
10 
Control (0% FCS) 33196 36625 34911 
FXIIIa (50 µg/mL) 39926 45723 42825 
 
 
Summary of effects and calculated average, standard deviation and standard error of mean of 
the invasion assays performed using primary culture cells are shown in Table B.8. 
 
Table B8: Summary of invasion assay using primary culture  
Experiment Control 
(0% FCS) 
Effect of FXIIIa 
(50 µg/mL) 
1 1 0.59 
2 1 0.83 
3 1 0.76 
4 1 0.45 
5 1 1.27 
6 1 1.08 
7 1 1.27 
8 1 1.08 
9 1 1.42 
10 1 1.23 
Average - 1.00 
Standard Deviation - 0.32 
SEM - 0.10 
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Appendix C: Raw data from zymography studies 
 
C.1 Substrate gel zymography using trophoblast cell line 
Conditioned medium from invasion assays using the trophoblastic cell line was studied with 
substrate gel zymography, and the intensity of the bands of the matrix metalloproteases 
MMP-9 and MMP-2 was quantified with Bio-1D software (Vilber Lourmat, France). The 
obtained values of volume intensity calculated by the software are given in Table C.1. 
Table C.1: Volume intensity of MMP-9 and MMP-2 secretion using trophoblast cell line 
Experiment Conditions 
Volume intensity of 
MMP-9 
Volume intensity of 
MMP-2 
1 
Control (0% FCS) 214862 229367 
FXIIIa (50 µg/mL) 215857 190586 
2 
Control (0% FCS) 192961 181473 
FXIIIa (50 µg/mL) 175876 178494 
3 
Control (0% FCS) 144034 165034 
FXIIIa (50 µg/mL) 172675 225263 
4 
Control (0% FCS) 179647 195562 
FXIIIa (50 µg/mL) 172520 208699 
 
Summary of effects and calculated average, standard deviation and standard error of mean of 
effect on matrix metalloproteases secretion using trophoblastic cell line are shown in Table 
C.2, using formula B.1, B.2 and B.3 given in Appendix B.  
 
Table C.2: Summary of effects of FXIIIa on MMP secretion using trophoblast cell line 
Experiment Control 
(0% FCS) 
Effect of  FXIIIa on 
MMP-9 secretion 
Effect of  FXIIIa on 
MMP-2 secretion 
1 1 1.00 0.83 
2 1 0.91 0.93 
3 1 1.20 1.36 
4 1 0.96 1.07 
Average 1 1.02 1.05 
St dev - 0.13 0.23 
SEM - 0.064 0.12 
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C.2 Substrate gel zymography using primary culture 
Conditioned medium from invasion assays using primary culture was studied with substrate 
gel zymography, and the intensity of the bands of the matrix metalloproteases MMP-9 and 
MMP-2 was quantified with Bio-1D software (Vilber Lourmat, France). The obtained values 
of volume intensity calculated by the software are given in Table C.3. 
 
Table C.3: Volume intensity of MMP-9 and MMP-2 secretion using primary culture 
Experiment Conditions 
Volume intensity 
of MMP-9 
Volume intensity 
of MMP-2 
1 
Control (0% FCS) 104793 109301 
FXIIIa (50 µg/mL) 105253 107199 
2 
Control (0% FCS) 85302 N.D. 
FXIIIa (50 µg/mL) 91342 N.D. 
3 
Control (0% FCS) 91306 124880 
FXIIIa (50 µg/mL) 92590 119811 
N.D.: Not detectable 
 
Summary of effects and calculated average, standard deviation and standard error of mean of 
effect on matrix metalloproteases secretion using primary culture are shown in Table C.4, 
using formula B.1, B.2 and B.3 given in Appendix B.  
 
Table C.4: Summary of effects of FXIIIa on MMP secretion using primary culture 
Experiment Control 
(0% FCS) 
Effect of  FXIIIa on 
MMP-9 secretion 
Effect of  FXIIIa on 
MMP-2 secretion 
1 1 1.00 0.98 
2 1 1.07 - 
3 1 1.01 0.96 
Average - 1.03 0.97 
St dev - 0.04 0.015 
SEM - 0.02 0.011 
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C.3 Substrate gel zymography using explants 
Conditioned medium from explants culture was studied with substrate gel zymography, and 
the intensity of the bands of the matrix metalloproteases MMP-9 and MMP-2 was quantified 
with Bio-1D software (Vilber Lourmat, France). The obtained values of volume intensity 
calculated by the software are given in Table C.5. 
Table C.5: Volume intensity of MMP-9 and MMP-2 secretion using explants 
Experiment Conditions 
Volume intensity 
of MMP-9 
Volume intensity 
of MMP-2 
1 
Control (0% FCS) 242703 203328 
FXIIIa (50 µg/mL) 245264 244962 
2 
Control (0% FCS) 268027 215148 
FXIIIa (50 µg/mL) 280145 225095 
3 
Control (0% FCS) 356128 415315 
FXIIIa (50 µg/mL) 355794 414981 
 
Summary of effects and calculated average, standard deviation and standard error of mean of 
effect on matrix metalloproteases secretion using primary culture are shown in Table C.6, 
using formula B.1, B.2 and B.3 given in Appendix B.  
 
Table C.6: Summary of effects of FXIIIa on MMP secretion using explants 
Experiment 
Control 
(0% FCS) 
Effect of  FXIIIa on 
MMP-9 secretion 
Effect of  FXIIIa on 
MMP-2 secretion 
1 1 1.01 1.20 
2 1 1.05 1.05 
3 1 1.00 1.00 
Average - 1.02 1.08 
St dev - 0.02 0.11 
SEM - 0.014 0.06 
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Appendix D: Raw data from proliferation studies 
 
D.1 Proliferation studies on trophoblast cell line using BrdU 
The effect of FXIII-A on proliferation was studied with BrdU incorporation. The initial 
experiment was conducted with 3000 cells/well in a 96-well plate after the existing technique 
in the laboratory. The measured absorbance was lower than expected (Table D.2), therefore a 
test of increasing cell dosage was performed and the result is shown in Table D.1. The net 
value of absorbance (blank absorbance measurement subtracted from sample absorbance) was 
plotted against cell quantity in Figure D.1. From the graph it was chosen to use 7.5*10^3 
cells/well since a higher quantity of cells would reach the plateau phase immediately. 
Absorbance measurements should be read after 10-15 minutes to reach the optimal 
absorbance interval.  
Table D.1: Increasing cell dosage test for proliferation studies using BrdU incorporation 
Cell 
quantity 
Absorbance 
after 5 min 
Absorbance 
after 10 min 
Absorbance 
after 15 min 
Absorbance 
after 20 min 
Absorbance 
after 30 min 
2.5*10^3 0.208 0.283 0.318 0.460 0.634 
5.0*10^3 0.275 0.387 0.523 0.610 0.610 
1.0*10^4 0.283 0.442 0.516 0.600 0.600 
5.0*10^4 0.384 0.519 0.639 0.740 0.890 
1.0*10^5 0.462 0.609 0.700 0.830 1.040 
Blank 0.0867 0.0875 0.0853 0.0881 0.0878 
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Figure D.1: Absorbance plotted against cell quantity for different time measurements. 
Absorbance was read after 5, 10, 15, 20 and 30 minutes for the different cell quantities.  
 
The absorbance measurements with and without effectors are given in Table D.2. 
Quadruplicates of each sample were conducted and the blank (substrate from BrdU kit only) 
was measured once. The average of the quadruplicates was calculated and used to find the 
effect of FXIIIa compared to the control (0% FCS). Formulas given in Appendix B were used 
in the calculation and the results are listed in Table D.3.  
Table D.2: Proliferation study on trophoblast cell line using BrdU incorporation 
Experi-
iment 
Conditions 
Absobance 
Parallell 1 
Absorbance 
Parallell 2 
Absorbance 
Parallell 3 
Absorbance 
Parallell 4 
1 
 
FCS (10%)  0.2042 0.2164 0.2695 0.2529 
FXIIIa (50 µg/mL) 0.2316 0.2030 0.2321 0.3123 
Control (0% FCS) 0.2087 0.2647 0.2368 0.2052 
Blank 0.1379 - - - 
2 
 FCS (10%) N.A. 0.6212 0.7815 0.9089 
FXIIIa (50 µg/mL) 0.7893 0.7957 0.8352 0.6818 
Control 0.6256 0.6358 0.9556 0.6965 
Blank 0.0751 - - - 
3 
FCS (10%) 0.6407 0.5584 0.5128 0.6308 
FXIIIa (50 µg/mL) 0.6357 0.8410 0.7373 0.7975 
Control 0.5643 0.9360 0.9740 0.5279 
Blank 0.0876 - - - 
N.A: No answer 
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Table D.3: Summary of effects of FXIIIa and serum on proliferation of trophoblast cell line 
Experiment Control  
(0% FCS) 
FXIIIa 
(50 µg/mL) 
FCS 
(10%) 
1 1 1.17 1.08 
2 1 1.07 1.06 
3 1 1.00 0.75 
Average 1 1.08 0.96 
St dev - 0.85 0.19 
SEM - 0.049 0.11 
 
D.2 Proliferation studies on explants using immunohistochemistry  
The effect of FXIII-A on proliferation was also studied by marking sections of explants with a 
proliferation marker (Ki67). The amount of nuclei in a proliferation state was counted with 
ImageJ computer software (National institutes of Health, Bethesda, MD). The surface ratio of 
the tissue was measured with the same software, and the proliferation ratio was calculated as 
shown in equation D.1. The counted nuclei and measured surface is listed in Table D.4. The 
effect of FXIII and serum (10% FCS) compared to the control (0% FCS) was calculated, as 
well as the average, standard deviation and standard error of the mean (using formulas given 
in Appendix B), which is listed in Table D.5.  
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Table D.4: Proliferation study on explants using immunohistochemistry 
Experiment Conditions 
Nucleus 
marked 
Surface 
Nucleus 
marked 
Surface 
Nucleus 
marked 
Surface 
1 
Control 82 329861 48 254620 68 334716 
FXIIIa 61 242532 62 239433 86 338931 
10% FCS 103 281383 95 325327 130 359629 
2 
Control 56 383725 68 381874 54 371568 
FXIIIa 63 344950 85 277742 32 291117 
10% FCS 163 415234 124 377876 145 390901 
3 
Control 49 379013 50 346856 178 370334 
FXIIIa 78 317553 93 357139 81 271596 
10% FCS 133 351170 113 362209 128 354222 
4 
Control 80 395816 76 415219 51 367832 
FXIIIa 49 342599 55 369433 96 347926 
10% FCS 81 320697 128 378992 57 392400 
5 
Control 169 335307 113 394613 117 390233 
FXIIIa 60 323784 60 238218 51 308152 
10% FCS - - - - - - 
6 
Control 82 329861 48 254620 68 334716 
FXIIIa 61 242532 62 239433 86 338931 
10% FCS 103 281383 95 325327 130 359629 
7 
Control 49 379013 50 346856 178 370334 
FXIIIa 78 317553 93 357139 81 271596 
10% FCS 133 351170 113 362209 128 354222 
 
 
Table D.5: Summary of effects of FXIIIa and serum on proliferation study using explants 
Experiment Control 
(0% FCS) 
FXIIIa 
(50 µg/mL) 
FCS 
(10%) 
1 1 1.19 1.59 
2 1 1.27 2.33 
3 1 1.07 1.40 
4 1 1.08 1.40 
5 1 0.55 - 
6 1 1.19 1.59 
7 1 1.07 1.40 
Average - 1.04 1.40 
St dev - 0.24 0.55 
SEM - 0.090 0.21 
 
 
